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I 
Abstract 
 
Nowadays, cancer still remains one of the leading causes of death in the world. Therefore, 
cancer research is a present and central topic. Current drawbacks in cancer therapeutics are 
the lack of tumor specificity and the inefficient drug accumulation in cancer cells, resulting in 
non-specific agents that also affect healthy cells and thus their application provokes many side 
effects. Many possibilities for cancer cell-selective targeting of drugs are currently in focus. 
One includes the use of cell-penetrating peptides (CPPs), which are able to overcome the 
plasma membrane barrier and to transport various cargoes inside cells. Recently, it was shown 
for some CPPs, that they can specifically target cancer cells and therefore be used to promote 
the effective transport of anticancer drugs into various neoplastic cells. Furthermore, a certain 
intracellular targeting feature to various organelles was presented in the last years, which is 
important for the successful delivery of certain drugs to their point of action. This makes these 
amino acid sequences a promising research field in cancer treatment. 
In this study, the focus was set to the development and characterization of specific cancer-
selective peptides that accumulate in the cell nuclei and can moreover be used to deliver 
various cargoes to cancer cells.  
The design of the CPPs was based on the C-terminal domain of the cationic antimicrobial 
peptide CAP18 (sC18), which was modified in various ways. For instance, it could be 
demonstrated that dimerization of the sequence and the N-terminally introduction of nuclear 
targeting sequences led to higher uptake rates of the CPP.  Furthermore, the branched variant 
(sC18)2 exhibited a certain cancer cell-selectivity and was able to disrupt the neoplastic plasma 
membranes resulting in higher cytotoxicity. Next to this, the combination of sC18 with N50 and 
NrTP - two sequences that specifically target the cell nuclei - are approving the intracellular 
trafficking into the cell nucleus in cancer cells. Furthermore, an application as drug delivery 
system in breast cancer cells was elucidated.   
II 
Zusammenfassung 
 
Krebs ist eine der häufigsten Todesursachen weltweit, weshalb die Forschung nach neuen 
Therapieansätzen zur Krebsbekämpfung eine zentrale Rolle annimmt. Die maßgeblichen 
Nachteile heutiger Therapien sind sowohl die ungezielte Ansteuerung von Krebszellen als 
auch eine ineffiziente Anhäufung der Medikamente in Tumoren. Das macht viele Therapeutika 
zu nicht zufriedenstellenden Lösungen, da diese ebenfalls gesunde Zellen angreifen und 
daher sehr viele Nebeneffekte mit sich bringen. Zurzeit sind viele andere Herangehensweisen, 
um Krebszellen spezifisch anzusteuern, im Fokus der Wissenschaft. Eine davon ist der Einsatz 
von zellpenetrierenden Peptiden (cell-penetrating peptides, CPPs), die in der Lage sind, sich 
selber in Zellen einzuschleusen und zusätzlich Wirkstoffe in diese zu transportieren. Kürzlich 
konnte für einige dieser CPPs gezeigt werden, dass sie Krebszellen spezifisch ansteuern und 
gleichzeitig als Transporter für Zytostatika dienen können. Außerdem haben einige Peptide 
die Eigenschaft, in speziellen Zellorganellen wie dem Zellkern zu akkumulieren, was nötig ist, 
um spezielle Medikamente an ihren Wirkungsort zu transportieren.  
In dieser Arbeit sollten Peptide entwickelt werden, die selektiv gegenüber Krebszellen sind. 
Weiterhin wurde untersucht, ob sich diese Peptide selektiv im Zellkern anlagern und als 
Transportsystem genutzt werden können.   
Das Design der neuen CPPs basierte auf dem Peptid sC18, eine von der C-terminalen 
Domäne des antimikrobiellen kationischen Peptides CAP18 abgeleiteten Sequenz. Dieses 
zellpenetrierende Peptid wurden auf unterschiedlichen Wegen modifiziert. Es konnte gezeigt 
werden, dass eine Dimerisierung über die Seitenkette eines Lysins zu höheren Aufnahmeraten 
und einer Lokalisation der Peptide im Zellkern führt. Für das verzweigte (sC18)2 konnte eine 
erhöhte Krebsselektivität gezeigt werden. Das Peptid sorgt für eine Permeabilisierung der 
Zellmembran von Krebszellen und induziert dadurch eine gewisse Zytotoxizität.  
Außerdem wurde sC18 durch das N-terminale Kuppeln von speziellen Zellkern-ansteuernden 
Sequenzen modifiziert. Die Kombination des Peptids mit N50 und NrTP – zwei 
Peptidsequenzen, die in der Lage sind, den Zellkern selektiv anzusteuern – führte zu einer 
erhöhten Anreicherung der Peptide im Nukleus von Krebszellen. Zudem konnte ein 
erfolgreicher Transport eines Therapeutikums in Brustkrebszellen gezeigt werden.  
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1 
1. INTRODUCTION 
 
1.1 Overcoming cell membrane barriers 
About four billion years ago, the first cells and with them, the primary cell membranes emerged. 
Cellular plasma membranes have a lot of duties and functions towards the cell. It is a semi-
permeable lipid bilayer, which defines the cell shape and separates the intracellular space from 
the surrounding environment, protecting the cell from invading pathogens and toxic 
substances. [1, 2] Due to their particular biological structure, the membrane is only permeable 
for small hydrophobic compounds with less than 1,000 Daltons [3]. Uptake of large or 
hydrophilic molecules can only occur through transmembrane protein channels and transporter 
molecules. Furthermore, cellular membranes are involved in various physiological processes 
such as signal transduction, energy synthesis and cell-cell communication. [4, 5] 
Since the plasma membrane has extraordinary properties in protecting the cell from the 
surrounding environment, the problem occurs that delivery processes of drugs, proteins and 
nucleotides into cells and compartments are limited. Several studies about strategies to 
overcome membrane barriers have received major attention in the last years. Penetration of 
the cellular plasma membrane can either be achieved by the use of certain biological or 
chemical compounds, like prodrugs, carriers and permeation enhancers, or by physical units 
generating an energy-dependent disruption of the membrane. [2] Within this, cell membranes 
have already been permeabilized by sonoporation, resulting in a successful gene delivery to 
HeLa and PC-3 cells [6, 7]. However, for most of the physical methods, a power source is 
necessary. Therefore, they can be potentially expensive, which reduces the attraction of these 
methods. A variety of biological approaches like prodrugs, liposomes and nanoparticles were 
recently developed and investigated. In this context, liposomes were shown to transport anti-
cancer, anti-fungal and antibiotic drugs as well as anti-inflammatory agents and gene 
medicines into a variety of cells [8]. Moreover, PEGylated nanoparticles have been used to 
deliver proteins and peptide-drugs in vivo [9]. 
Another group of transport vehicles has been discovered in the last decades; these are short 
peptides, able to cross membranes in a receptor-independent manner. These so-called cell-
penetrating peptides (CPPs) have the ability to interact electrostatically with biological 
membranes and internalize into a number of different cell types, like microorganisms, fungi, 
mammalian and plant cells. [10, 11] In general, they are known to be usually positively charged, 
water soluble and partly hydrophobic. Advantages of these peptides are their small size, good 
biocompatibility and their easy and cost-effective synthesis. Furthermore, CPPs can be easily 
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modified concerning, for example their affinity, hydrophobicity, charge, solubility, and stability. 
Additionally, they do usually not evoke an immune response. [12, 13] The most important 
feature of these recently discovered peptides is certainly their capability to efficiently transport 
different cargos into cells [14]. Anyway, also disadvantages of CPPs are known, like their low 
cell, tissue and organ specifity and their limited stability in vivo. Moreover, another problem to 
overcome is their often occurred internalization by endocytosis and the need of a subsequent 
endosomal release, essential for the transport of peptides and cargos to their targets. [15] 
Nevertheless, cell-penetrating peptides represent a promising and precious tool for the 
transport and internalization of otherwise impermeable molecules.  
 
1.2 Commonly used cell-penetrating peptides 
Cell-penetrating peptides can be divided into different subgroups based on their specific 
properties. One classification is based on the origin of the peptide sequence divided in protein-
derived, chimeric or synthetic peptides. [10] An overview about some CPPs and their 
sequences is presented in table 1.  
 
Table 1: Examples for commonly used cell-penetrating peptides and their origin. 
Peptide Sequence Origin Reference 
TAT(48-60) GRKKRRQRRRPPQ Protein-
derived 
[16] 
Penetratin RQIKIWFQNRRMKWKK Protein-
derived 
[17] 
hCT(9-32) LGTYTQDFNKFHTFPQTAIGVGAP Peptide-
derived 
[18] 
sC18 GLRKRLRKFRNKIKEK Protein-
derived 
[19] 
(sC18)2                             GLRKRLRKFRNKIKEK 
                                    | 
GLRKRLRKFRNKIKEK 
Chimeric [20] 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL Chimeric [21] 
Oligoarginines R8, R9, R10, R12 Designed [22] 
Pep-1 KETWWETWWTEWSQPKKKRKV Designed [23] 
 
 
 
The peptides TAT and penetratin are examples for CPPs that are derived from natural proteins. 
TAT(48-60) is a cationic and hydrophilic peptide derived from the transcription activating factor 
Introduction 
 
3 
of human immunodeficiency virus (HIV-1), that is able to translocate through the plasma 
membrane and accumulate in the cell nucleus. [16] Also penetratin is derived from a 
transcription factor, precisely from the Drosophila Antennapedia homeodomain, and is an 
extensively studied cell-penetrating peptide. Penetratin is declared to be a secondary 
amphipathic peptide, meaning that its amphipathic structure is only formed when the CPP is 
interacting with phospholipid membranes. [17] Furthermore, also a hydrophobic peptide, 
derived from the human peptide hormone calcitonin (hCT) has been reported to translocate 
membranes. The shorter fragment hCT(9-32) is able to transport small organic molecules as 
well as proteins into cells. The efficient delivery of DNA and RNA has been reported for 
hCT(18-32), which was further combined with a lysine- and arginine-rich sequence (k7), 
representing an example for a chimeric peptide built from a peptide-derived and designed 
sequence. [18, 19, 24] Another well-studied CPP is derived from a cationic antimicrobial protein 
from rabbit leucocytes, which is assumed to inactivate pathogens by permeabilizing their 
membranes. This cathelicidin-derived, short peptide sequence from the C-terminal domain is 
called sC18 and exhibits an α-helical structure. It was already demonstrated that its uptake 
rates are comparable to those of TAT(48-60) and hCT(18-32)-k7. [19, 25] Furthermore, also a 
branched, dimeric version of sC18 was examined by Hoyer et al. with even higher 
internalization capacity and an increased cytotoxicity. (sC18)2 is also able to efficiently 
transport cytostatic compounds into tumor cells. [20]   
Transportan is classified as a chimeric CPP, which is composed of two sequences, 
mastoparan and galanin. Mastoparan is known as a wasp toxin that can penetrate and lyse 
cell membranes, while galanin is a neuropeptide, which inhibits the release of neurotransmitter 
from vesicles. Their chimeric combination connected via a lysine results in a cell-penetrating 
peptide with high internalization rates. [21] Examples for synthetically designed peptides are 
Pep-1 and oligoarginines. The amphipathic peptide Pep-1 was shown to deliver unbound 
active proteins or peptides into cells and different oligoarginines were reported to translocate 
through membranes due to their high hydrophilicity. [22, 23]  
 
1.3 Cellular uptake mechanisms of cell-penetrating peptides 
The cellular uptake of cell-penetrating peptides is a complex process, which is intensively 
studied. Unfortunately, the general uptake mechanism is still not fully understood, since the 
internalization of peptides can occur in several ways simultaneously. Moreover, the uptake is 
dependent on the peptide sequence, the concentration, temperatures as well as the cell type 
investigated. In addition, specific cargoes attached to the CPP can also influence the uptake 
mechanism. Generally, two different ways of CPP entry are discussed – the direct translocation 
over the membrane and the uptake via endocytosis. [26, 27] 
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Direct penetration is an energy-independent process that can even occur at low temperatures 
when all endocytotic uptake routes are repressed. Hereby, it is thought that the mainly 
positively charged peptides interact electrostatically with negatively charged components of 
biological membranes, inducing finally the insertion of the peptide in the membrane and 
resulting in cell entry. In this context, the internalization by inverted micelles, direct 
translocation, pore formation, carpet-like model and membrane thinning can be differentiated 
as shown in figure 1.   
   
 
Figure 1: Overview of the main mechanisms of cellular internalization used by cell-penetrating 
peptides among non-endocytotic direct penetration ways, with representative corresponding 
examples. [28] 
 
For penetratin for example, the translocation via inverted micelles has been shown, whereby 
the membrane is destabilized and a curvature is induced. The formed micelle is then enclosing 
the peptides in its interior and the disruption of the inner membrane is resulting in the release 
of the CPPs into the cytoplasm. [29] Pore-formation, which is presumed for transportan can 
arise via the barrel stave or the toroidal model. The CPPs organize in barrel-like structures, 
where the hydrophilic residues of the sequences form the pore, or as in the toroidal model, the 
peptides and headgroups of membrane lipids built the pore together. [10]  
Also the endocytic uptake pathway, which is an energy-dependent process, can be classified 
in various mechanisms like macropinocytosis, clathrin- or caveolin-dependent or -independent 
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endocytosis as depicted in figure 2. After endosomal uptake, the CPPs and CPP-cargo 
conjugates are enclosed in vesicles. The following endosomal release is a challenging 
mechanism, and also indispensable for the effect of many drugs taken up by endocytosis. [30] 
Moreover, the uptake and release depends, among others, on the size and physicochemical 
nature of the cargo molecule [31].   
 
 
Figure 2: Overview of the main mechanisms of cellular internalization used by cell-penetrating 
peptides among endocytotic-based mechanisms, with representative corresponding examples. 
[28] 
 
For the well-studied TAT(48-60) peptide, various uptake routes have been demonstrated 
including a direct penetration, but also macropinocytosis, as well as clathrin- or caveolin-
independent internalization could be presented [28]. During macropinocytosis an inward 
folding of the plasma membrane to the outer surface takes place and results in a vesicle inside 
the cell [32]. The different uptake ways are dependent on concentration, time of incubation and 
composition of membrane phospholipids. [33, 34] NrTP analogues, which are also used in this 
thesis, crosses the cell membrane by clathrin-dependent endocytosis. [35]  
For the cathelicidin-derived CPP sC18, an endocytotic uptake pathway is supposed, but a 
more precise declaration is still in study [19]. Also for the dimeric variant (sC18)2, internalization 
by endocytosis was postulated, which was further investigated in this study [20].  
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1.4 Cell-penetrating peptides for selective targeting of 
cancer cells 
Cancer remains one of the main causes of death globally, and it is one of the most common in 
the United States responsible for nearly 25% of deaths. A majority of treatments includes the 
surgical removal of the tumor tissue. Furthermore, chemo- and radiotherapy are used to inhibit 
tumor growth – nevertheless, a major issue is that also healthy tissue is affected by these 
therapeutical approaches. [36, 37] The major drawbacks of cancer therapeutics are not only 
the lack of tumor specificity, but also drug resistance, inefficient drug accumulation and cancer 
cell heterogeneity. The traditional chemotherapeutic systems poorly distinguish between 
cancer and non-cancer cells, leading to non-negligible side effects. [12] Hence, a broad field 
of scientific studies try to find solutions to specifically target cancer cells and prevent the 
affection of healthy cells.  
From this point of view, CPPs have been intensively studied and discussed, since for some of 
them showed a tumor targeting ability. Interaction, binding and translocation depends on the 
components of the extracellular matrix of the cell membrane as well as on their sugar and lipid 
composition.  In fact, plasma membranes of cancer and non-cancer cells differ from each other, 
as neoplastic cell membranes have an increased amount of anionic molecules such as the 
phospholipid phosphatidylserine, sialylated gangliosides, O-glycosylated mucins and heparin 
sulfate. This results in a more negative net charge in contrast to healthy mammalian cell 
membranes, which occur mostly zwitterionic. [38, 39] Especially positively charged CPPs are 
able to interact with the more negatively charged cancer cell membranes, which is primarily 
responsible for their tumor cell selectivity. The positively charged, amphipathic peptide NK-2, 
which is derived from the cationic core region of an antibacterial effector protein from porcine 
immune cells, specifically attacks cancer cells that have a high content of phosphatidylserine. 
Healthy human lymphocytes are not harmed by this membranolytic peptide. [40] Lim et al. 
presented in 2013 a derivative of the anticancer peptide buforin IIb with extraordinary cancer-
specificity. This peptide BR2 targets cancer cells by interaction with gangliosides, which are 
found in high amounts within tumor cells, and translocates the membrane via lipid-mediated 
macropinocytosis. [41]  
Another strategy to specifically target cancer cells is the combination of cell-penetrating 
peptides with homing peptides, which are able to recognize particular cell types. Homing 
peptides are often membrane impermeable, which could be advanced by the conjugation to 
CPP sequences. Tumor homing peptides usually interact with receptors that are 
overexpressed on the cancer cell surface like integrins, somatostatin, transferrin or epidermal 
growth factor receptors (EGFR). [12] The conjugation of a CPP with S3, an EGFR-binding 
domain from vaccinia virus growth factor, increases the tumor selectivity extremely. The uptake 
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rates of the conjugate were 80-times higher than of the peptide alone, whereas the 
internalization in non-cancer cells remained at a low level. [42] The tripeptide Arg-Gly-Asp 
(RGD) is often used for the specific targeting of integrins because this sequence is specifically 
recognized by the transmembrane receptors. Recently, a study was published, whereby an 
RGD reverse sequence was conjugated to octaarginine. This conjugation peptide could 
specifically bind to integrin αvβ3, which is highly upregulated in some tumors, and translocate 
into various cancer cells with increased uptake rates compared to the controls. [43, 44]   
 
1.5 Application of CPPs as delivery vectors in cancer cells  
Very recently, in last August 2017, the company Novartis introduced the first chimeric antigen 
receptor T cell therapy on the market, which is based on gene transfer for the treatment of 
B-cell precursor acute lymphoblastic leukemia [https://novartis.gcs-web.com/novartis-
receives-fda-approval-for-KymriahTM (29.09.2017)]. For this immunocellular therapy, named 
Kymriah, the patient's T-cells were taken and transduced with a lentiviral vector encoding a 
specific antigen receptor for the overproduced B-cells in this type of cancer. Transferring the 
cells back to the patient, they are able to express the antigen and the immune system starts 
to fight the cancerous B-cells. [45] In clinical phase II, 83% of the patients treated with the new 
therapy achieved complete remission, even if the treatment is associated to many side effects 
[Novartis media release, Basel, August 30, 2017].  
A challenging process in this new treatment is the transfection of the T-cells with the lentiviral 
vector. In general, it is not just important to target specific cells with an application system, but 
also the transport capability of these systems should be reliable. Anyway, based on this 
example, there are some promising methods to treat cancer besides the use of conservative 
therapies like resection or chemotherapy. 
Also cell-penetrating peptides received attention as potential candidates for anticancer drug 
delivery systems. [12] These peptides were shown to transport biologically active cargoes such 
as drugs, proteins, peptides, nanoparticles and nucleic acids into cells. CPPs were also used 
as anticancer peptidic vaccines in various approaches. [46, 47] Li et al. presented the 
amphipathic peptide CADY-1, which is able to form a stable complex with the cytotoxic anti-
cancer drug doxorubicin (DOX) and triggers its transport over the cell membrane increasing its 
toxicity. This CADY-1/doxorubicin complex even exhibits anti-tumor activity in animals. [48]  
Also TAT-DOX conjugates were investigated, showing a high decrease in viable cells 
compared to the incubation with TAT or DOX alone. They were even able to overcome the 
multidrug resistance of cervical cancer cells by circumventing drug efflux. [49] A human ovarian 
cancer cell line that is resistant to the chemotherapeutic agent taxol was treated efficiently with 
a conjugate of taxol and octaarginine. The approach to overcome this taxol resistance was 
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next to cell culture also observed in mouse models with ovarian cancer. [50] The CPP BP16 
with delivery features for the anticancer drug chlorambucil was presented by Soler et al. The 
efficacy of chlorambucil increased between 6 and 9-times when linked to BP16 in various 
cancer cells. [51] Also other compounds used in tumor therapy were transported to target cells, 
for example organometallic compounds, like cisplatin, were efficiently carried by the well-
studied CPP Transportan 10 to two different cell lines, whereas no internalization of the drug 
in non-cancer cells could be observed [52].  
For the above described recently introduced immunocellular gene therapy, a delivery of nucleic 
acids, in this case a DNA vector, is necessary. In this topic, a high number of studies with 
successful delivery by CPPs could be published. Mussbach et al. demonstrated in 2011 that 
various cell-penetrating peptides in non-covalent complexes with nucleoside phosphates were 
able to transport them in high amounts into a cervix cancer cell line. Their binding to functional 
proteins in signal transduction or translation process can induce many intracellular reactions. 
[53] The delivery of RNA or DNA is exceedingly challenging, because these nucleic acids need 
to be non-covalently bound to the CPPs and transported to the nuclei as well. This so-called 
transfection was first described in 1997 by Morris et al. using a 27 residue-long peptide 
sequence built from a hydrophobic domain of HIV gp41 and a hydrophilic domain from the 
nuclear localization sequence of SV40 T-antigen. They showed a rapid and efficient delivery 
into the nucleus of fibroblasts by the formation of peptide vector/oligonucleotide complexes. 
[54] But also in cancer cells, transfection could be successfully conducted by CPPs. The basic 
amphiphilic peptide ppTG1 is efficiently triggering the transport of vector DNA into HeLa cells. 
The luciferase reporter assay presented gene expression rates comparable to standard 
transfection reagents as polyethylenimine (PEI) and Lipofectin. [55] A short cell-penetrating 
peptides (RRWQW) from bovine lactoferrin was presented to deliver a plasmid, encoding the 
enhanced green fluorescent protein (EGFP) into human lung carcinoma cells, which was 
subsequently expressed. Also the efficiency of this peptide was comparable to the commonly 
used transfection reagent Lipofectamine. [56] 
 
1.6 Specific targeting of organelles using CPPs 
Many cargoes or drugs need in fact to be transported to specific targets within the cell. Some 
of them are depicted in figure 3. Especially organelles like mitochondria, the Golgi apparatus 
or the nucleus can be reached combining cell-penetrating peptides with a specific localization 
sequence. This intracellular targeting is a very promising feature of these peptides.  
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Figure 3: Uptake mechanisms and intracellular targeting of organelles. [15] 
 
The so called mitochondria-penetrating peptides composed of a CPP and a mitochondria-
targeting sequence are of great interest, since a lot of intracellular processes as intermediary 
metabolism, calcium signaling and apoptosis are controlled by these energy-generating 
organelles. Furthermore, a high number of human diseases such as Parkinson’s disease are 
caused by mitochondrial dysfunctions [57, 58]. The uptake and mitochondrial localization of a 
mitochondria-penetrating peptide in two cancer cell lines (HeLa and MCF-7) could already be 
demonstrated by Horton et al. [59].  
Moreover, of a great interest is the targeting of the cell’s control center, the nucleus. This 
organelle contains the genetic information and controls cell growth, development and 
reproduction as well as many other intracellular processes. The nuclei are enveloped by a 
nuclear membrane that separates the nucleoplasm from the cytoplasm and protects the DNA 
from the surrounding cytoplasm [60, 61]. For some CPPs, an accumulation in the nuclei could 
be demonstrated. For example, the well-studied trans-activator of transcription TAT(48-60) is 
able to translocate through the plasma and nuclear membrane [16]. But also some nuclear 
localization sequences (NLS) were presented in the last years, natural as well as synthetic 
ones. NLS sequences can be found in cellular or viral proteins that need to be transported to 
the nucleus after translation or viral infection of a host cell. They often contain high amounts 
of lysines and arginines. After covalent attachment of a nuclear localization signal motif of the 
Introduction 
 
10 
Simian-Virus 40 (SV40)-T-antigen (PKKKRK) to a peptide, derived from dermaseptin, which 
failed to enter the nuclei, the conjugate was accumulating in this compartment of HeLa cells 
[62]. Lewis et al. showed that the synthesis of a novel CPP consisting of a glutamate-rich 
peptide (EEEAA) coupled to the nuclear localization signal of the Oct6 transcription factor 
results in nuclear localization as well as uptake in prostate and pancreatic cancer cell lines 
[63].    
Nuclear factor-κB (NFκB) is a family of structurally related transcription factors bearing an 
essential role in inflammation, innate immunity and cancer development. The protein complex 
that controls DNA transcription is imported into the nucleus through the nuclear pores by 
importin. The NFκB1/p50 subunit contains a hydrophilic N50 motif patterned on its NLS region. 
This N50 motif is known to bind the importin α and is therefore responsible for the efficient 
transport of the transcription factor into the cell nucleus. [64, 65] This N50 peptide sequence 
(VQRKRQKLMP) was used in this thesis for nuclear targeting of CPPs. 
Another desirable target for intracellular delivery of drugs, transcription factors and siRNAs is 
the nucleolus. A cell contains between one and five of these dense granular structures in the 
nucleus, which are mostly composed of RNA and proteins. The ribosomal RNA transcription 
and synthesis of ribosome subunits takes plays in this compartment, and is involved in viral 
infection, regulation of oncogenesis and tumor suppression. [66, 67] For D-octa-arginine an 
accumulation in the nucleoli could be reported by Fretz et al. [68]. Lately, NrTP was designed 
by structural minimization of the rattlesnake toxin crotamine. The peptide sequence showed 
strong membrane-translocating properties and it was capable to penetrate various carcinoma 
cells and accumulate in their nucleoli. This sequence contains a lysine-rich palindrome hexad 
in the middle of the peptide (YKQCHKKGGKKGSG). Also the capability of NrTP for intracellular 
delivery of large molecules like β-galactosidase has been previously demonstrated. [35, 69] 
The NrTP peptide sequence was used in this thesis to target cell nucleoli.  
 
1.7 Preliminary work 
This work is based on the studies that were performed during my master thesis. In this context, 
the dimeric cell-penetrating peptide (sC18)2 was investigated regarding its internalization, 
toxicity and membrane interaction in comparison to the monomeric sC18. 
In this recent work, it could be shown that sC18 does not exhibit toxicity to three studied cancer 
cell lines (MCF-7, HeLa and HCT-15) and the non-cancer cell line HEK-293. In contrast, it 
could be executed that the toxicity of (sC18)2 is extremely increased when incubated with the 
cancer cell lines HeLa and MCF-7 compared to HCT-15 and HEK-293 cells. Moreover, (sC18)2 
presumably acts via disrupting the plasma membranes of HeLa and MCF-7 cells. 
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Also the internalization of the dimeric versus the monomeric peptide differed from each other, 
which was verified by microscopic studies. It was observed in all cell lines that the 
internalization rates of (sC18)2 were much higher compared to the uptake of the monomeric 
sC18. Furthermore, a detailed observation of a non-cancer and a cancer cell line presented, 
that sC18 and (sC18)2 seemed to internalize in HEK-293 cells via an endocytic uptake way. 
Afterwards, the peptides were entrapped in the vesicles and did not appear in the nucleus. On 
the contrary, in MCF-7 cells, the peptides were distributed in the cytoplasm as well as in the 
nucleus, which could be explained by an endocytotic uptake with followed release from the 
endosomes or a direct translocation over the plasma membrane. It is also likely that both 
uptake ways occur simultaneously. The high internalization rates and the accumulation in the 
nuclei is probably correlated with the cytotoxic effect on MCF-7 cells. The difference in cancer 
and non-cancer cells was further investigated using an artificial membrane-like system, 
precisely different composed giant unilamellar vesicles (GUVs). In this context, it was 
demonstrated that the interaction of the peptides with negatively charged membranes is much 
higher than with GUVs composed of zwitterionic phospholipids, which is in accordance with 
the fact that the peptides showed increased penetration rates and lytic effects on the negatively 
charged cancer cell membranes. 
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2. AIMS OF THE THESIS  
The main goal of this thesis was the development and characterization of cancer-selective and 
nuclei-targeting cell-penetrating peptides. Therefore, the well-studied CPP sC18 was chosen 
as candidate and modified in several ways.  
In part I (“Linear and branched dimeric versions of sC18”) new variants of sC18 should 
therefore be developed and characterized. The focus was set on the dimerization of sC18 and 
its truncated form sC18* (lacking the four C-terminal amino acids). The aim was to investigate 
the impact of the dimerization strategy that yielded either linear or branched derivatives. 
Therefore, all new peptides should be analyzed concerning their cell-penetrating and 
membrane damaging properties. In this regard, internalization studies via flow cytometer and 
microscopy, but also cytotoxicity experiments and furthermore, studies with artificial membrane 
systems should be performed.   
The first part revealed that (sC18)2 showed the highest anticancer potential. Therefore, the 
focus was set on this peptide in part II of the thesis (“Characterization of a CPP with 
potential anticancer activity”). Within this part, the detailed uptake mechanism and cell 
selectivity were of great interest. Therefore, uptake studies in different cancer and non-cancer 
cell lines, studies about the uptake pathway and cargo delivery should be performed. The 
investigation should initiate with different uptake studies with various peptide concentrations 
and temperatures. Also flow cytometric analysis should be performed, as well as endosomal 
release experiments. Next to membrane interaction and disruption studies, also a screening 
on 16 different cell lines should be performed to further prove the cancer selectivity of the 
peptide. As a last approach, the drug transport capability should be investigated.    
For the delivery of various cargoes, it is important that the transport is not just triggered over 
the plasma membrane. It is also necessary that the transport vehicle is able to deliver the cargo 
to its point of action, which could be for example the nucleus. In the third part (“Specific 
targeting of nuclei and nucleoli using modified CPPs”) the CPP sC18* should be combined 
with the two nuclear localization sequences N50 and NrTP. These fusion peptides should be 
investigated concerning their translocation efficiency, nuclear localization and toxicity in MCF-7 
and HeLa cells. Furthermore, their capability to form complexes with plasmid DNA and the 
followed transfection ability should be elucidated, as well as the non-covalently conjugation of 
an anticancer drug and its delivery into cancer cells.  
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3. MATERIALS AND METHODS 
 
3.1 Materials 
 
3.1.1 Chemicals 
All chemicals, reagents and consumables used in this work were purchased from Alfa Aesar 
(Karlsruhe, Germany), Applichem (Darmstadt, Germany), Fluka (Taufkirchen, Germany), 
Merck (Darmstadt, Germany), Roth (Karlsruhe, Germany) Sarstedt (Nürmbrecht, Germany), 
Sigma-Aldrich (Taufkirchen, Germany) and VWR (Darmstadt, Germany), if not specified 
otherwise. Nα-Fmoc protected amino acids were obtained from IRIS Biotech (Marktredwitz, 
Germany). 
 
3.1.2 Instrumentations  
Balances   
     
Analytical balance FA-210-4, Faust 
Laboratory balance SBA52, Scaltec  
CD spectrometer Jasco Corp. J715 
Cell culture clean bench Heraeus Herasafe HS12 
Centrifuges Multifuge X1R, Thermo Scientific 
Pico 17, Thermo Scientific 
CO2-Incubator  BINDER 
ESI mass spectrometer   Bruker Esquire HCT 
Flow cytometer Guava easyCyte, Merck 
Hemocytometer Neubauer improved, Superiour Marienfeld, Germany, Depth 
0.100 mm, 0.0025 m2 
Heating block Thermomixer compact, Eppendorf 
HPLC (analytic) Hewlett Packard Series 1100, Agilent 1100 Series 
column: Phenomenex Kinetex, 2,6 u, C18, 100A,  
100 x 4,60 mm or Machery Nagel, C18ec Elite Lachrom 
Hitachi Pump L-2130, Elite 
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HPLC (preparative) Elite Lachrom Hitachi Pump L-2130, Elite Lachrom 
Hitachi Autosampler L-2200, Elite Lachrom Hitachi 
Diode Array Detector L-2455, Teledyne ISCO Fraction 
Collector Foxy R1, column: Phenomenex Jupiter,  
4 u Proteo 90 A, 250 x 15 mm, 4 micron or Machery 
Nagel, C18ec 
LC - mass spectrometer LC: Hewlett Packard Series 1100 
MS: Finnigan MAT – LCQ or MS: Thermo Scientific 
LTQ-XL 
Lyophilizer Lyovac GT2 with CertomaT SII and a Thermo Savant 
Refridgerated Vapor Trap RVT5105 or Christ; Alpha 2-4 
LDplus 
Microscope Inverted microscope (Motic AE31, Wetzlar) 20x 
objective (N.A. 0.25)) Confocal laser scanning system 
(Nikon D-Eclipse C1), inverted microscope (Nikon 
Eclipse Ti), 60x oil immersion objective (N.A. 1.4, Plan  
PO VC; Nikon)  
Multipette® plus Eppendorf Research 
NanoDrop NanoDrop™ 1000 Spectrophotometer, Thermo Scientific 
PCR Thermal Cycler FlexCycler analytikjena 
Pipetting aid  NeoLab 
Pipettes Eppendorf Research 
Plate reader Tecan infinite M200 
Rotary Shaker KL-2 (Edmund Bühler GmbH) 
Spectrophotometer Thermo Scientific Genesys 10S UV-Vis 
Speed-Vac Thermo Scientific Speedvac Concentrator Savant SC210A, 
RVT5105 Refrigerated Vapor Trap VLP80 Vacuum Pump 
Synthesis robot MultiSynTech Syro I 
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Thermomixer compact Eppendorf 
Vacuum pump VWR 
Vortex  Scientific Industries – Vortex Genie 2 
Water bath Julabo SW22 
XcelVapTM Horizon Technology 
   
3.1 Methods 
 
3.1.1 Peptide synthesis 
All syntheses were performed in open polypropylene reactor vessels (2 ml syringes) stocked 
with a fritted filter disc. Manual coupling steps were performed under the hood and solvents 
were removed from the resin using a vacuum pump.   
For each synthesis 15 µmol of resin were used and calculated according to the specific resin 
loading. The mentioned equivalents correlated with the amount 15 µmol per equivalent. 
Following to all coupling steps a Kaiser test was performed to examine the presence of free 
amino groups and the completeness of a coupling. If the test was positive, the coupling step 
was repeated. 
Since carboxyfluorescein is light sensitive, all experiments including CF-coupling, as well as 
all following steps were executed avoiding light, and all peptides were protected from light by 
covering with aluminum foil. 
The theoretical molecular masses were calculated using the software Peptide Companion, 
Version 1.25, CoshiSoft/PeptiSearch or the peptide property calculator by Innovagen, 2015. 
 
2.3.1.1 Automated peptide synthesis 
For automated peptide synthesis, a multiple Syro I peptide synthesizer from MultiSynTech was 
used. The software SyroXP is able to calculate the amounts of amino acids that are needed to 
synthesize the peptides. All amino acids were dissolved in DMF except from phenylalanine 
that needed to be dissolved in NMP. After filling the reaction vessels with 15 µmol (30 mg) of 
Fmoc-Rink amide resin beads and starting the software, the robot performs all synthesis steps 
automatically using the Fmoc/t-Bu strategy. In the first step, the beads were swollen in DMF 
and the Fmoc protection group was cleaved from the resin using first a 40% piperidine solution 
in DMF and afterwards a 20% piperidine solution in DMF. After washing the beads four times 
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with DMF, coupling of the first Nα-Fmoc protected amino acid was performed using Oxyma and 
DIC. The amino acid was introduced in 8-fold excess and every coupling step was performed 
twice, each for 40 min respectively including four washing steps with DMF in between. Before 
repeating deprotection and coupling of the next amino acid, the sample was washed another 
time with DMF. In the last step, the vessels were again incubated with piperidine to cleave off 
all Fmoc protection groups and washed four times with DMF. After the complete synthesis, the 
samples were washed with CH2Cl2, MeOH and Et2O manually and the resin beads were dried 
in the Speedvac.  
 
2.3.1.2 Coupling procedure with Oxyma/DIC 
For the manual coupling of amino acids, the resin was swollen for 15 min in 1 ml DMF at RT 
shaking with 200 rounds/min. After removing the solvent with a vacuum pump, a solution 
containing the amino acid (7 eq. for general amino acids, 2 eq. for Dde-L-Lys-(Fmoc)-OH) and 
Oxyma (7 or 2 eq.) in 300 µl DMF and 7 or 2 eq. of DIC was added to the resin, respectively. 
The solution was incubated for 2 h or o/N at RT and under shaking conditions. After washing 
the resin five times with DMF, the coupling procedure was repeated. In the end, the solvent 
was removed, the resin was washed five times with DMF, CH2Cl2, MeOH and Et2O, 
respectively, and afterwards it was dried for 10 min at low speed in the Speedvac.  
 
2.3.1.3 Kaiser test (after Kaiser et al. 1970) 
To monitor whether the coupling was successful and all free amino groups were successfully 
coupled with an amino acid, a protection group or carboxyfluorescein, a Kaiser test was 
performed on a few resin beads [70]. After transferring some beads into a 1.5 ml reaction 
vessel, one drop of the solutions I to III (table 2) was added in quick succession.  
 
Table 2: Chemicals used for the Kaiser test. 
Solution I 1.0 g ninhydrin in 20 ml EtOH 
Solution II 80 g phenol in 20 ml EtOH 
Solution III 0.4 ml aq. KCN-solution (1 mM) in 20 ml pyridine 
 
 
The mixture was incubated at 95 °C for 5 min in a Thermomixer. The test was defined positive, 
if the solution showed a blue color, indicating free amino groups. If the mixture was yellow, no 
free amino groups could be detected and the coupling was complete. 
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2.3.1.4 Cleavage of a Dde protecting group 
To cleave the special Dde protecting group, the resin was swollen for 15 min in 1 ml DMF at 
RT. After removing the solvent, 1 ml of a 3% hydrazine solution in DMF was added to the resin 
and incubated for 10 min. The solvent was collected in a Falcon tube, the resin was washed 
twice with DMF and the flow through was harvested in the same Falcon tube. This procedure 
was performed ten times, collecting just the last phase. The amount of Dde in the first and the 
last sample was determined by measuring the absorption at 301 nm in a spectrophotometer. 
A mixture of 2 ml DMF and 1 ml 3% hydrazine served as reference. If the absorption of the last 
washing step was lower than 0.1, the entire cleavage of the Dde group was successful. If it 
was higher than 0.1, a few cleavage steps with 3% hydrazine were repeated. Afterwards the 
resin was washed five times with DMF, CH2Cl2, MeOH and Et2O, respectively, and dried for 
10 min at low speed in the Speedvac.  
 
2.3.1.5 Cleavage of an Fmoc protecting group 
Before coupling the following amino acid in the coupling procedure, the Fmoc protecting group 
had to be cleaved off. Therefore, the resin was swollen for 15 min in 1 ml DMF, the solvent 
was removed and 500 µl of a 30% piperidine solution in DMF was added. The resin was 
incubated shaking for 20 min at RT and afterwards washed five times with DMF. The procedure 
was done twice.  
 
2.3.1.6 Coupling of carboxyfluorescein 
For the modification of the peptide with the reporter group carboxyfluorescein, the resin was 
swollen as described previously and after removing the solvent, a solution was added that 
contained 10 eq. 5(6)-carboxyfluorescein and 10 eq. HATU in 300 µl DMF. Afterwards, 10 eq. 
DIPEA were pipetted directly to the resin. The syringe was shaken at RT for 2 h. After washing 
the resin five times with DMF the coupling was repeated o/N using Oxyma and DIC as 
described above. Thereafter, the resin was washed five times with DMF, CH2Cl2, MeOH and 
Et2O respectively and dried for 10 min at low speed in the Speedvac. The successful coupling 
was verified by a Kaiser test.  
If the test was negative, a polymer cleavage was performed to avoid CF polymers. Therefore, 
the resin was swollen in DMF, 1 ml of a 20% piperidine solution in DMF was added and the 
syringe was incubated shaking for 45 min at RT. In the end, the resin was washed five times 
with DMF, CH2Cl2, MeOH and Et2O, respectively, and dried for 10 min at low speed in the 
Speedvac.  
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2.3.1.7 Coupling of DOTA and NODAGA 
The N-terminal coupling of the chelators DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid – Sigma Aldrich) and NODA-Ga(tBu)3 (4-(4,7-bis(2-tert-butoxy-2-oxoethyl)-
1,4,7-triazonan-1-yl)-5-tert-butoxy-5-oxopentaoic acid – CheMatech / Dijon, France) was 
carried out in the same way as described for CF except from using 3 eq. of the substance to 
be coupled and activating with 3 eq. HATU/DIPEA in DMF under vigorous shaking for 2 h. A 
double coupling process was not desired. 
After full cleavage and preparative HPLC (chapter 2.3.1.9 and 2.3.1.11), a salt exchange was 
done to eliminate the TFA salts in the peptide solution. Therefore, the lyophilized CPPs were 
dissolved in 5 ml of 80 mM HCl solution and incubated at RT shaking for 1 h. After freezing the 
sample for 30 min at - 80 °C, it was dried o/N by lyophilisation. The procedure was repeated 
two to four times, until no TFA adducts could be detected via analytical ESI-MS spectrometry 
anymore. 
 
2.3.1.8 Sample cleavage 
A sample cleavage was done to ensure that the manual coupling of amino acids, CF or chelator 
and the synthesis of the robot was successful. Some dry beads of the resin were transferred 
to a 1.5 ml tube and 2.5 µl of the scavenger triisopropylsilane mixed with 2.5 µl H2Odd was 
added. After the addition of 95 µl TFA using a multipette, the syringe was incubated at RT 
shaking for 3 h. Peptide sequences that contain cysteine,  methionine  or  tryptophan were 
cleaved from the resin with 7 μl thioanisole, 3 μl 1,2-ethandithiole and 90 µl TFA. The peptide 
was precipitated in 1 ml of ice-cold diethyl ether and the mixture was incubated for at least 
20 min at - 20 °C. The samples were centrifuged at 10,000 x g for 5 min at 4 °C. After removing 
the supernatant, the pellet was again resuspended in 1 ml ice-cold ether and centrifuged for 
5 min at 10,000 x g at 4 °C. This procedure was repeated at least five times until no scavenger 
smell could be noted anymore. The pellet was then dried for 10 min at low speed in the 
Speedvac. After resuspending the peptide in 100 µl H2O or H2O/tBuOH (3:1 (v/v)) according to 
the solubility, the sample was centrifuged for 1 min at 10,000 x g to separate the beads from 
the peptide and the supernatant was analyzed via HPLC/ESI-MS (chapter 2.3.1.10).  
 
2.3.1.9 Full cleavage 
To cleave the peptides from the resin, a full cleavage was performed. A mixture of 25 µl of the 
scavenger triisopropylsilane and 25 µl H2Odd was added to the resin. After the addition of 950 µl 
TFA using a multipette, the syringe was incubated at RT shaking for 3 h. Peptide sequences 
that contain cysteine, methionine or tryptophan were cleaved from the resin with 70 μl 
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thioanisole, 30 μl 1,2-ethandithiole and 900 µl TFA.  To precipitate the peptide, the solvent was 
pressed through the fritted disc in a 15 ml Falcon tube containing 10 ml of ice-cold diethyl 
ether. Furthermore, 200 µl of TFA were added to the resin and also harvested in the tube. After 
incubation for at least 20 min at - 20 °C to allow precipitation of the peptide, the sample was 
centrifuged at 5,000 x g for 5 min at 4 °C. The supernatant was removed, the pellet was 
resuspended in 10 ml ice-cold diethyl ether and the solution was again centrifuged. This 
procedure was repeated five times until no scavenger smell could be noted anymore. The 
pellet was then dried for 15 min at low speed in the Speedvac and afterwards resuspended in 
2 ml H2O or H2O/tBuOH (3:1 (v/v)), respectively. The peptide solution was transferred into a 
balanced glass vessel and covered with paper. After freezing the sample for 30 min at - 80 °C, 
it was freeze-dried o/N by lyophilisation. The amount of the peptide could then be detected by 
weight and after subtraction of the TFA residues that bind to all free NH2-ends and the side 
chains of the positively charged amino acids arginine and lysine. 
 
2.3.1.10 Analytical high performance liquid chromatography- 
electrospray ionization mass spectrometry (HPLC/ESI-MS) 
For the identification of the synthesized sequences, a high performance liquid 
chromatography/electrospray ionization mass spectrometry (HPLC/ESI-MS) method was 
performed. After sample or full cleavage from the resin, peptides were usually diluted 1:10 with 
10% ACN/90% H2O containing 0.1% trifluoroacetic acid or formic acid, depending on the 
chosen method. Generally, the peptides were separated on the column with a flow rate of 
6 ml/min via an increasing linear gradient from 10 – 60% ACN in H2O (inclusive 0.1% TFA or 
FA). After the HPLC, the sample passed the electrospray ionization source, whereby ions were 
generated and their m/z ratios were determined. 
 
2.3.1.11 Preparative reverse phase high performance liquid 
chromatography (RP-HPLC) 
After lyophilisation, the dry peptide, but not more than 30 mg, was dissolved in 960 µl of 
ACN/H2O (incl. 0.1% TFA) according to the initial ratio of gradient and centrifuged in a 1.5 ml 
tube for some seconds to separate the sample from possible debris. The supernatant was 
transferred to a bellied HPLC glass vessel.  
The purification of the peptide was done with a preparative HPLC and the software 
EZChromElite. First, the column was equilibrated with ACN/H2O (incl. 0.1% TFA) according to 
the start gradient. Afterwards, the concentration of ACN was increased gradually and the 
peptide containing fractions were collected. The solvent was removed via evaporation in the 
XcelVap at 65 °C using a gradient of 880 – 1640 mbar twice for 30 min, respectively. 
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Afterwards, 15 µl were taken for the analytical HPLC and the rest was transferred to balanced 
glass vessels and covered with paper. After freezing the samples for 30 min at - 80 °C, they 
were freeze-dried by lyophilisation o/N.  
According to the weight and the purity, the dried peptides were dissolved in H2Odd to a 
concentration of 1 mM regarding the accumulation of TFA on every arginine, lysine and free 
NH2-group at the terminal end. 
 
2.3.2 CD spectroscopy 
For the structural characterization of the synthesized peptides, circular dichroism spectra were 
recorded. The cell-penetrating peptides were analyzed in 10 mM potassium phosphate buffer 
(pH 7.0) with and without TFE (1:1 dilution), respectively. Therefore, 20 µM peptide solutions 
in the two different buffers were measured in 3 accumulations in the CD spectrometer 
according to the apparatus instructions. The peptides were measured in a 0.1 cm quartz 
cuvette with a sensitivity of 100 mdeg in the range from 260 to 180 nm in 0.5 nm intervals. The 
scanning mode was continuous and a scanning speed of 50 nm/min was chosen. The results 
of pure buffer were subtracted from the spectra of the peptides. The ratio between the molar 
ellipticity at 222 nm and 207 nm is a good indicator to confirm an α-helical structure of peptides. 
For α-helices, these R-values should be around a value of one. [71] 
 
2.3.3 Cell culture methods 
All cell culture work was done in sterile conditions under the sterile hood wearing disinfected 
gloves. All working materials that were transferred under the hood were disinfected with 70% 
EtOH before using. Autoclaved pipette tips and sterile serological pipettes were used for the 
cell culture work. A vacuum pump was utilized to remove media during washing or splitting 
steps.  
All cell lines were grown in sterile culture dishes (diameter 10 cm) in a CO2-Incubator (5% CO2) 
at 37 °C. The cell line HEK-293 was grown in MEM containing 15% Fetal Bovine Serum (FBS) 
and 4 mM L-Gln. The cell lines HeLa, HCT-15 and MCF-7 were grown in RPMI-1640 medium 
containing 10% FBS and 4 mM L-Gln. For PC-3 cells, DMEM F-12 Ham’s medium was 
completed with 4 mM L-Gln and 5% FBS. HaCaT cells were grown in high glucose DMEM 
supplemented with 2 mM L-Gln and 10% FBS. Each medium was also prepared without FBS. 
 
2.3.3.1 Mycoplasma testing 
All used cell lines were tested at least once a year but anywhere after taking new cell lines in 
culture using the PCR Mycoplasma Test Kit II and the Superhot Taq DNA Polymerase provided 
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by Applichem following the manufacture´s protocol. After the polymerase chain reaction using 
the supernatant of centrifuged consumed medium of cells, 6x loading dye was added to the 
samples which were then loaded on a 1.5% agarose gel stained with GelRed™ (Biotium, USA) 
in Tris Acetate-EDTA (TAE) buffer and electrophoresed for 40 min at 100 V. 
 
2.3.3.2 Splitting and seeding cells 
For trypsinization of the cells, the cell layer was washed twice with 4 ml of phosphate buffered 
saline (PBS). To detach the cells from the surface and from each other, 1 ml of Trypsin-EDTA 
solution was added and incubated for 3 – 15 min at 37 °C, depending on the cell line. 
Detachment of cells was checked microscopically in bright-field mode with a 20x objective 
(N.A. 0.25)). Cells were then resuspended and mixed with 9 ml of medium containing serum 
to inhibit trypsin activity.  
To split the cells, they were transferred to new culture dishes and mixed with new medium 
depending on the splitting ratio. Cells were grown in approximately 10 ml fresh medium. The 
number of passages was mentioned on each plate, HEK-293 cells were not used above the 
30th passage and HeLa, HCT-15, MCF-7 and PC-3 cells not above the 40th passage. HaCaT 
cells could be used until passage number 100. 
For seeding a defined number of cells, a hemocytometer was used for cell counting. Therefore, 
10 µl of the cell suspension was pipetted between the hemocytometer and the cover slip. The 
cells in 4 squares (volume of each 1 x 10-4 ml) were counted under the microscope, divided by 
4 to get the average number of one square, and multiplied with 104 to get the number of cells 
per ml. The determined concentration was used to calculate the needed volumes to seed the 
requested amount of cells.  
 
2.3.3.3 Freezing and thawing cells 
To freeze cells, they were trypsinized and after adding medium to inhibit trypsin activity, they 
were centrifuged for 5 min at 300 x g. After removing the supernatant, the cell pellet was 
resuspended in 1.5 ml freezing medium (requested medium containing FBS and Gln and 10% 
sterile filtered DMSO), transferred to a freezing tube and cooled down at 4 °C for 15 min. 
Afterwards, the tubes were stored at - 20 °C for 2 – 4 h and then incubated o/N at - 80 °C. The 
next day, the tubes were transferred into liquid nitrogen. 
To thaw cells, the freezing tubes were taken from liquid nitrogen and put on ice. The solution 
was thawed at 37 °C in the water bath and directly transferred to a culture dish containing the 
required medium. After incubation in the CO2-Incubator (5% CO2) at 37 °C for 24 h, dead cells 
and rests of DMSO were removed by washing the cell layer twice with PBS before adding new 
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medium. HaCaT cells were centrifuged and the cell pellet was resuspended in fresh medium 
before transferring them into TC Flask T75, Cell+ from Sarstedt. After satisfying growth, cells 
were transferred in usual culture dishes.  
 
2.3.4 Cell viability assay based on resazurin 
To detect the relative cell viability after treatment with the CPPs in various concentrations, a 
cytotoxicity assay was performed. The first day, a total volume of 200 µl of cells (HEK-293 
7*104, HeLa, PC-3 and HaCaT 4*104, MCF-7 and HCT-15 5*104 cells per well) were seeded 
in 96-well plates. 
After approximately 24 h of incubation at 37 °C, when the cells reached a confluency about 
80%, the medium was removed and the peptide or substance solutions diluted in serum-free 
medium were added in a total volume of 100 µl to the cells. In the wells that served as positive 
and negative controls, the medium was replaced by fresh medium missing FBS. The plates 
were incubated for 24 h or 48 h at 37 °C.  
Afterwards, the positive control was treated with 100 µl of 70% EtOH for 10 min. In the 
meantime, the other wells were washed with PBS as well as the positive control in the end. To 
start the reaction, cells were covered with 100 µl of a 10% resazurin solution in medium without 
FBS and incubated for 1 – 2 h at 37 °C. Afterwards, the fluorescent product of the reaction, 
namely resorufin was quantified by measuring the fluorescence with the Tecan infinite M200 
plate reader (Excitation: 550 nm, Emission: 595 nm).  
To achieve comparably results, the positive control was in most of the cases subtracted from 
all data and the negative control was set to 100%, so that the results of the peptide treated 
cells represent relative cell viability values in %.   
 
2.3.5 Cell lysis assay based on LDH release 
The CytoTox-ONETM Homogenous Membrane Integrity Assay from Promega was performed 
to detect disrupted cell membranes. Thereby, the released lactate dehydrogenase from 
permeabilised cells can be monitored. The first day, a total volume of 200 µl of cells (HEK-293 
7*104, HeLa and PC-3 4*104, MCF-7 and HCT-15 5*104 cells per well) were seeded in 96-well 
plates. The next day, the wells, except for the ones of the positive and negative control, were 
treated with the peptide or substance solutions in medium without FBS for 1 h at 37 °C. After 
the plate was brought to room temperature, 2 µl of lysis solution from the Kit were added to 
the positive control. The CytoTox-ONETM reagent was prepared as described in the protocol 
and 100 µl were added to each well. The cells were incubated at RT for 10 min before stopping 
the reaction with 50 µl of stop solution also provided with the kit. The release of LDH was 
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monitored via measuring the fluorescence using the plate reader Tecan infinite M200 
(Excitation: 560 nm, Emission: 590 nm).  
The results are shown in relative cell lysis compared to the average value of the positive 
control, which was set to 100%, after subtraction of the fluorescent intensity of the negative 
control, which represents the background LDH release. 
 
2.3.6 Microscopy  
For microscopic analyses, a confocal laser scanning system (Nikon D-Eclipse C1) with an 
inverted microscope (Nikon Eclipse Ti) was used. The pictures were taken with the 60x oil 
immersion objective (N.A. 1.4, Plan APO VC; Nikon) and the software EZ-C1 3.91 from Nikon.  
The cells were seeded in 350 µl medium in an 8-well ibidi plate (HEK-293 1.2*105, HeLa 
4.5*104, MCF-7 7*104, HCT-15 2*105, PC-3 8*104, HaCaT 1.2*105 cells per well) and were 
grown to 70 – 80% confluency. The next day, the medium was removed and the cells were 
treated with the peptides and substances in various concentrations for the requested time 
periods. The cells were incubated at 4 °C or 37 °C and 10 min prior to the end of incubation 
0.6 µl of Hoechst stain (bisbenzimide H33342, 1 mg/ml in H2O, sterile filtered) was added to 
each well to stain the cell nuclei. After removing the solutions, the cells were quenched with 
200 µl of 150 µM trypan blue solution (in acetate buffer) for 30 s. The stain was removed and 
the cells were washed twice with medium. After adding 300 µl of fresh medium, pictures were 
taken under the microscope with pinhole S, Offset green: 100, blue: 38, red: 0 and various gain 
values. The gains for the blue and red channel were individually chosen due to the fact, that 
the staining was different depending on the mixing after addition of Hoechst, Lysotracker or 
ER-tracker and the cell density. The images were edited in Image J 1.43m. 
 
2.3.7 Flow cytometry 
For flow cytometric analyses, cells were seeded the day before (HEK-293 5*105, HeLa 1.7*105 
and MCF-7 2*105 cells per well) in 24-well plates and grown to 70 – 80% confluency o/N. Then, 
the cells were treated with 400 µl of peptide or substance solutions dissolved in serum-free 
medium for the appropriate time at 4 °C or 37 °C. Afterwards, the cells were washed twice with 
PBS and detached using 200 µl of Trypsin-EDTA 1X in PBS without phenol red for 3 – 5 min 
followed by adding 800 µl of indicator-free medium. The cells were resuspended and 200 µl of 
the suspension were transferred to a 96-well plate for measuring the fluorescence in the guava 
easy cyte flow cytometer. In each sample, 10’000 cells were measured and each experiment 
was done in triplicate. Cells treated with medium only served as negative control and their 
fluorescent signal was subtracted from all other samples in each set of experiment.  
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2.3.8 Radiolabeling of the NODAGA-coupled peptides and uptake 
experiments 
The following experiments were done in cooperation with Sergio Muños Vázquez and Beate 
Zimmermanns in the working group of Prof. Dr. Klaus Schomäcker in the Department of 
Nuclear Medicine, University of Cologne.  
The radioisotope [68Ga]Ga3+ was eluted in 0.05 M ultrapure HCl from a 68Ga/68Ga generator 
(Isotope Technologies Garching GmbH). For the labeling of [68Ga]Ga-NODAGA-sC18, a stock 
solution was prepared with 1 mg of peptide dissolved in 1235 ml of ultrapure water; 30 ml of a 
stock solution (10 nmol) was mixed with 15 ml of 2 M sodium acetate buffer; 200 ml of the 
eluted 68Ga (50 – 70 MBq) was added to the reaction vial resulting in a solution at pH 4.5. For 
the labeling of [68Ga]Ga-NODAGA-(sC18)2, a stock solution was prepared with 2 mg of peptide 
dissolved in 1339 ml of ultrapure water; 30 ml of a stock solution (10 nmol) was mixed with 
15 ml of 2 M sodium acetate buffer; 200 ml of the eluted [68Ga]Ga3+ (50 – 70 MBq) was added 
to the reaction vial resulting in a solution at pH 4.5. The labeling mixture was incubated for 
30 min at RT, respectively. The radiochemical yield was determined by HPLC, which was 
performed with Azura ASM 2.1L equipped with two P4.1S pumps with pressure transducer and 
10 ml titanium pump head, a degasser DG 2.1S 2-channels, a Smartmix 350 mixer and a 
manual 6-port/3-channel injection valve with a sample loop of 20 ml. The compounds were 
analyzed by a Nucleodur C18 Gravity, 250 mm x 4 mm, 5 mm column and a linear A – B 
gradient (80% A to 70% A in 15 min) at a flow rate of 1 ml/min. Solvent A consisted of H2O 
containing 0.1% TFA, and solvent B was ACN with 0.1% TFA. The compounds were analyzed 
by a UV detector UVD2.1L (λ = 254 nm) and the radioactive ones were determined by a 
radioactivity counter STEFFI Raytest. The peak analyses were done by OpenLAB CDS 
EZChrom edition version A.04.05.  
For uptake studies, HEK-293 and MCF-7 cells were seeded in 24-well plates. The next day, 
when they were grown up to 80% confluency, the peptides were added to the cells in serum-
free medium and incubated for 30 min. Afterwards, the cells were washed twice with PBS and 
detached with trypsin-EDTA. The cells were centrifuged and the radioactivity in the cell pellet 
was determined in a gamma spectrometer (LB2045 Berthold technologies). 
 
2.3.9 Plasmid transformation in E.coli and plasmid isolation 
For plasmid transformation, competent Escherichia coli DH5α cells, produced with the CaCl2 
method [72], were kindly provided by Annika Klimpel. An aliquot of competent cells was thawed 
on ice and gently mixed with 0.5 µl of vector DNA (pEGFP-N1 or pGL4.13). After an incubation 
of 30 min on ice, the cells were heat shocked at 42 °C for 45 s and incubated for another 2 min 
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on ice. Thereafter, 500 µl of LB-medium (25 g Luria/Miller in 1 l H2Odd) without antibiotics were 
added and shaken for 45 min at 37 °C. 50 µl of the solution were plated on an LB agar plate 
with the appropriate antibiotic (100 µg/ml ampicillin) and incubated o/N until colonies are 
grown. The next day, colonies were picked using sterile pipette tips and transferred to 3 ml of 
LB-medium containing ampicillin. The cultures were incubated under vigorous shaking o/N and 
thereafter, the PureYield™ Plasmid Miniprep System from Promega was used following the 
manufacture´s protocol to isolate the plasmid. The vector concentration was determined with 
a NanoDrop and the plasmids were stored at - 20 °C.  
 
2.3.10 Electrophoretic mobility shift assay 
An electrophoretic mobility shift assay (EMSA) was performed to examine if the positively 
charged CPPs are able to form complexes with negatively charged plasmid DNA, namely the 
vectors pEGFP-N1 and pGL4.13. The peptides were incubated with the plasmid DNA in 
various charge ratios (1:1, 5:1, 10:1 and 30:1) for 30 min in 37 °C warm nuclease free water 
at RT in a total volume of 40 µl. Afterwards, the solution was supplemented with 8 µl 6x loading 
dye and around 30 µl were loaded on a 1% agarose gel in TAE-buffer (Tris-acetate-EDTA) 
stained with GelRed™ (Biotium, USA). The DNA was electrophoresed for around 30 min at 
100 V and the gel was then observed in a gel documentation system. Naked plasmid DNA was 
used as negative control.  
 
2.3.11 Examination of transfection with pEGFP-N1 plasmid 
For transfection with the enhanced green fluorescent protein encoding plasmid pEGFP-N1, 
cells were seeded in an 8-well ibidi plate (HeLa 4.5*104, MCF-7 7*104 cells per well) and grown 
to 70 – 80% confluency. Then, the CPPs N50-sC18* or NrTP-sC18* were complexed with the 
pEGFP-N1 vector in 50 µl nuclease free water as described before (2.3.10), the solution was 
filled up with 250 µl medium without FBS and added to the cells. Additionally, in one set of 
experiments, 100 µM chloroquine was added to the complexation solution. The plasmid itself 
served as negative control, cells treated with plasmid and Lipofectamine®2000 transfection 
reagent (ThermoFisher scientific), that were complexed for 5 min, were used as positive 
control. After 6 h incubation, the solution was replaced by fresh serum-free medium. 48 h later, 
the nuclei were stained with Hoechst and the cells were observed under the microscope.  
 
2.3.12 Examination of transfection with pGL4.13 plasmid  
For transfection with the luciferase encoding plasmid pGL4.13 [luc2/SV40], cells were seeded 
in 96-well plates (HeLa 4*104, MCF-7 5*104 cells per well). The next day, the CPPs N50-sC18* 
or NrTP-sC18* were complexed with the pGL4.13 [luc2/SV40] vector in 100 µl medium without 
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FBS as described before (2.3.10) and added to the cells. Additionally, in one set of 
experiments, 100 µM chloroquine was added to the complexation solution. Plasmid alone 
served as negative control, cells treated with plasmid and Lipofectamine®2000 transfection 
reagent (ThermoFisher scientific), that were complexed for 5 min, were used as positive 
control. After 6 h incubation, the solution was replaced by fresh serum-free medium and the 
cells were incubated for 48 h at 37 °C. Afterwards, the luciferase activity was determined using 
the ONE-Glo™ Luciferase Assay System by Promega. The solution was brought to RT and 
100 µl were added to each well without removing the medium, respectively. After 3 min of 
incubation at RT, the solutions were transferred to white 96-well polystyrol plates with clear 
bottoms and the luminescence was measured in the Tecan infinite M200.  
 
2.3.13 Cargo delivery of actinomycin D or doxorubicin 
For cargo delivery studies using the drugs actinomycin D or doxorubicin, cells were seeded in 
96-well plates (HeLa 4*104, MCF-7 5*104 cells per well). The day after, the drug alone or co-
incubated with the respective peptides in various concentrations were added in 100 µl to the 
cells and incubated for 24 or 48 h. Afterwards, a resazurin based cell viability assay was 
performed as described previously (2.3.4).  
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4 RESULTS AND DISCUSSION 
 
4.1 Linear and branched dimeric versions of sC18  
Previous studies have shown that the dimerization and branching of the cell-penetrating 
peptide sC18 led to higher uptake rates and membrane disrupting properties. In addition, the 
dimeric sequence (sC18)2 seemed to have a certain selectivity for cancer cells, as 
demonstrated by the different internalization patterns between cancerous versus 
non-cancerous cells. [Gronewold, master thesis 2014] [20] 
The branched variant (sC18)2 represents just one of many examples of structures derived from 
the CPP sC18. In other experiments, it was observed that a shorter variant of sC18 lacking the 
four C-terminal amino acids Ile-Lys-Glu-Lys could improve the formation of the α-helical, 
amphipathic structure. In this truncated version sC18*, the positively charged face of the helix 
is not interrupted by glutamic acid as in sC18, as presented in figure 4. The cell-penetrating 
ability of sC18* could be observed in HEK-293 and MCF-7 cells [73].   
 
 
Figure 4: Helical wheel projection of sC18 and sC18*. The projection is showing the hydrophilic 
(circles), hydrophobic (diamonds), potentially negatively (triangles), and positively charged (pentagons) 
residues. The most hydrophobic residues are represented in green and the amount of brightness is 
decreasing proportionally to the hydrophobicity, with zero hydrophobicity coded as yellow. Hydrophilic 
residues are coded red with pure red being the most hydrophilic (uncharged) residue. The charged 
residues are light blue. Projection was made with the software created by Don Armstrong and Raphael 
Zidovetzki. Version: Id: wheel.pl,v 1.4 2009-10-20 21:23:36 don Exp 
(http://rzlab.ucr.edu/scripts/wheel/wheel.cgi). 
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Until now, it was not elucidated, if the positive effects of (sC18)2 are a consequence of to the 
simple dimerization of the sC18 sequence or the branching. To figure this out, a linear version 
lin(sC18)2 containing two sC18 sequences in line was examined. Furthermore, the truncated 
sC18* was investigated as well as its dimeric versions (sC18*)2 and lin(sC18*)2. All peptides 
were synthesized via solid-phase peptide synthesis, cleaved from the resin, purified and used 
for further studies. For localization and uptake studies, CF-labeled sequences were also 
generated. The successful synthesis of the linear and branched variants was confirmed by 
HPLC/ESI-MS and in table 3 the calculated and experimentally obtained molecular masses, 
purities, yields and net charges are shown. All peptide sequences could be synthesized in 
satisfying purities and yields. Subsequently, the synthesis of a branched variant is exemplarily 
shown.  
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Table 3: Calculated and experimentally determined molecular weights, purities and yields of the synthesized sC18 derivatives, unlabeled and 
labeled with carboxyfluorescein (CF).  The peptides (sC18*)2 and CF-(sC18*)2 were provided by Dr. Stephanie Natividad-Tietz.  
Peptide Sequence 
MW
calc
 
[Da] 
MW
exp
 
[Da] 
Net 
charge 
Purity 
[%] 
Yield 
[%] 
sC18 GLRKRLRKFRNKIKEK-NH2 2069.60 2070.47 + 9 > 99 ~ 36 
CF-sC18 CF-GLRKRLRKFRNKIKEK-NH2 2427.92 2428.89 + 8 > 98 ~ 36 
(sC18)2 
                            GLRKRLRKFRNKIKEK-NH2 
                                    | 
GLRKRLRKFRNKIKEK 
4122.16 4122.44 + 17 > 99 ~ 22 
CF-(sC18)2 
                      CF-GLRKRLRKFRNKIKEK-NH2 
                                    | 
GLRKRLRKFRNKIKEK 
4480.50 4481.81 + 16 > 98 ~ 30 
sC18* GLRKRLRKFRNK-NH2 1570.96 1571.36 + 8 > 99 ~ 29 
CF-sC18* CF- GLRKRLRKFRNK-NH2 1929.28 1929.76 + 7 > 97 ~ 32 
(sC18*)2 
                    GLRKRLRKFRNK-NH2 
                            | 
GLRKRLRKFRNK 
3124.91 3125.04 + 15 > 98 ~ 43 
CF-(sC18*)2 
              CF-GLRKRLRKFRNK-NH2 
                            | 
GLRKRLRKFRNK 
3483.23 3483.30 + 14 > 97 ~ 49 
lin(sC18)2 GLRKRLRKFRNKIKEKGLRKRLRKFRNKIKEK-NH2 4122.16 4122.05 + 17 > 99 ~ 38 
CF-lin(sC18)2 CF-GLRKRLRKFRNKIKEKGLRKRLRKFRNKIKEK-NH2 4480.50 4480.36 + 16 > 99 ~ 39 
lin(sC18*)2 GLRKRLRKFRNKGLRKRLRKFRNK-NH2 3124.91 3126.10 + 15 > 99 ~ 44 
CF-lin(sC18*)2 CF-GLRKRLRKFRNKGLRKRLRKFRNK-NH2 3483.23 3482.99 + 14 > 99 ~ 51 
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The synthesis of (sC18*)2 was performed by SPPS from the C- to the N-terminus using the 
Fmoc/tBu-strategy. The synthesis strategy with the single steps is shown in figure 5. 
 
 
Figure 5: Reaction scheme of the stepwise peptide synthesis of the branched (sC18*)2. The 
grey circle represents a rink amide resin bead and the single steps 1 - 4 are explained in the running 
text.  
 
The sequence RLRKFRNK, anchored to the resin, was automatically synthesized by the 
robot. After the cleavage of the Fmoc protection group from the arginine at the N-terminus, 
the amino acid Dde-L-Lys-(Fmoc)-OH was manually coupled. Importantly, the lysine carries 
a special Dde protection group at the amino group and an Fmoc protection group at the 
ε-amino group of the side chain (figure 5-1). The peptide was then extended by automatized 
synthesis with the sequence GLRKRLRKFRNK at the side chain. The glycine at the 
N-terminus of this second chain was Boc-Gly-OH (figure 5-2). A sample cleavage was 
performed and analytic HPLC-ESI/MS proved successful synthesis of this fragment (data 
not shown). In the next step, the three missing amino acids GLR needed to be coupled to 
the peptide chain. Due to the presence of the Boc-protected glycine, an elongation of this 
sequence of the peptide was avoided. Instead, the Dde group of the manually bound lysine 
was cleaved off from the peptide chain using hydrazine and the amino acids GLR were 
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coupled manually using the activating reagents Oxyma and DIC. After labeling with 
5(6)-carboxyfluorescein (figure 5-3), the peptide was cleaved from the resin with TFA. In 
the end, the product was identified via HPLC/ESI-MS and purified by preparative HPLC. 
The UV chromatogram and ESI-MS spectra of the purified CF-(sC18*)2 are depicted in 
figure 6. 
 
 
Figure 6: Analysis of CF-(sC18*)2 by HPLC-ESI/MS. UV chromatogram (A) and ESI-MS (B) from 
analytic HPLC of (sC18*)2 labeled with carboxyfluorescein after preparative HPLC using a gradient 
of 10 to 60% acetonitrile in water containing 0.1% TFA. The four-fold to eight-fold charged 
pseudomolecular ions are marked and comply with the calculated ones ([M+4H]4+ = 871.81; [M+5H]5+ 
= 697.65; [M+6H]6+ = 581.54; [M+7H]7+ = 498.60; [M+8H]8+ = 436.40). 
 
The two main peaks in the UV chromatogram in figure 6 correspond to the two isomers of 
the 5(6)-carboxyfluorescein-labeled peptide. Successful synthesis of the CF-labeled cell-
penetrating peptide CF-(sC18*)2 could be confirmed by ESI-MS.  
 
4.1.1 CD spectroscopy of linear and truncated versions 
Peptides or proteins that are able to interact with biological membranes of cells or 
organelles, often contain secondary structures as α-helices or β-sheets [10]. To gain a first 
insight about the cell-penetrating capability of the sequences, the secondary structure 
formation was investigated by circular dichroism spectroscopy.  
In previous work, it was already shown, that the peptides sC18 and (sC18)2 display a 
random coil structure when measured in phosphate buffer environment. On the contrary, 
when the secondary structure inducing solvent trifluoroethanol is present, they exhibit an 
α-helical structure. [19, 20] Furthermore, it was shown that the fluorophore 
carboxyfluorescein has no significant influence on the formation of the secondary structure 
and hence on uptake, activity and properties of CPPs [74]. It is probable, that, like in the 
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presence of TFE, the peptides also exhibit α-helical structures when interacting with cell 
membranes. [75, 76] 
However, the newly synthesized peptides were measured in the CD spectrometer with a 
concentration of 20 µM in phosphate buffer (pH 7) with and without TFE, respectively. The 
spectra are shown in figure 7. 
 
 
Figure 7: Secondary structure analysis of CPP variants. Circular dichroism spectra of the 
investigated peptides sC18, sC18*, (sC18)2, (sC18*)2, lin(sC18)2 and lin(sC18*)2. Peptides were 
measured in a concentration of 20 µM in 10 mM phosphate buffer (pH 7) with (B) and without (A) 
50%-trifluoroethanol (TFE) (n = 1). 
 
All investigated peptides exhibited a random coil structure in phosphate buffer (figure 7 A), 
whereby in the presence of trifluoroethanol they all built an α-helical structure, even if the 
intensities of the amplitudes appeared to be different depending on the structures. The 
spectrum of sC18* in phosphate buffer with TFE showed a notable lower intensity in the 
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peak amplitudes, which is maybe due to its shorter sequence. The graphs of the peptides 
(sC18*)2 and lin(sC18*)2 have very similar shapes, probably because of the same amino 
acid composition. The higher intensities of the amplitudes visible in the spectrum of the 
lin(sC18)2 can be explained because its sequence is longer than the others. To confirm the 
formation of α-helices, the R-value, which is calculated by the quotient between the molar 
ellipticity at 222 nm and 207 nm, can be adduced. Thereby, a perfect formed helix results 
in the R-value of one. In table 4, the values corresponding to all peptide variants, which 
were measured in buffer containing TFE, are shown.  
 
Table 4: Calculated R-values [Ө222/ Ө207] of the synthesized peptides in phosphate buffer with 
50% TFE. 
Peptide R-value [θ222 / θ207] 
sC18 0.85 
sC18* 0.84 
(sC18)2 0.82 
(sC18*)2 0.82 
lin(sC18)2 0.89 
lin(sC18*)2 0.84 
 
It can be seen that all values were close to one, supporting the visual determination of 
α-helices. The values of the linear versions were slightly higher compared to the 
corresponding branched dimeric versions, which indicated a more regular helix formation. 
The sequences of the branched variants are interrupted by the peptide bond over the lysine 
side chain, which is probably resulting in a disruption of the helix. In contrast to that, the 
linear versions can probably form a continuous helix. 
Anyway, it can be concluded, that neither the dimerization, nor the branching of sC18 and 
sC18* disturbs the formation of helices and therefore, all peptides should be theoretically 
able to interact with biological membranes.   
 
4.1.2 Uptake studies using different sC18 variants  
Next, the internalization of the branched and linear dimeric versions of sC18 and sC18* 
were examined. Recently, studies using sC18 and (sC18)2 were published, indicating a 
difference in the uptake and localization in the non-cancer cell line HEK-293 and the breast 
cancer cell line MCF-7 [77]. Hence, these two cell lines were chosen to get an overview 
about the uptake and localization of the new variants. After incubating the cells for 30 min 
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with 10 µM of the peptides, the external fluorescence was quenched and the cells were 
observed under the fluorescence microscope, as shown in figure 8. 
 
 
Figure 8: Uptake of CPP variants in MCF-7 and HEK-293 cells. Fluorescence microscopy images 
after 30 min incubation with 10 µM CF-sC18, CF-sC18*, CF-(sC18)2, CF-(sC18*)2, CF-lin(sC18)2 and 
CF-lin(sC18*)2. Blue: Hoechst nuclear stain, Green: carboxyfluorescein-labeled peptides, external 
fluorescence was quenched with trypan blue for 30 s, Scale bars are 10 µm. 
 
Notably, all peptides seemed to have cell-penetrating properties and they seemed to 
behave differently in their uptake mechanisms and intracellular distribution depending on 
the tested cell line. All CPPs showed apparently higher internalization into the cancer cell 
line MCF-7 than into the non-cancer cells. To be more precise, in HEK-293 cells, the 
peptides presumably internalized by endocytosis, accumulating in vesicles, which could be 
detected by the punctual distribution within the cytoplasm. Furthermore, they were not 
present in the nucleus, which is a consequence of the fact that the peptides were probably 
hold in the endosomes and could thereby not enter the nuclei. Comparing the patterns of 
the different CPPs, it seemed that the internalization of sC18* is not that efficient as the 
uptake of the longer, parent peptide sC18. Florian Reichart showed in his dissertation by 
microscopy and flow cytometry experiments with 10 µM peptides, that the uptake of the 
truncated version is similar to the uptake of sC18 in HEK-293 cells, while in MCF-7 cells the 
internalization is reduced for sC18* compared to the longer sC18 [Reichart, Dissertation 
2015]. The uptake rates and intracellular distribution of the four dimeric variants were higher 
compared to the sC18 but within these CPPs, no obvious difference could be registered. 
In contrast, for MCF-7 cells, it can be seen that the uptake for all peptides probably occurred 
via direct penetration and endocytosis with a subsequent endosomal release, as the CPPs 
accumulated within the cytoplasm as well as within the nucleus. This can just occur, when 
the peptides are free in the cytoplasm and not trapped in endosomes. In detail, looking at 
the differences between the peptides, one can see that the internalization rates of sC18* 
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are reduced compared to the longer sC18 peptide. As already pointed out for HEK-293 
cells, the internalization rates of the dimeric, branched and linear versions, respectively, are 
much higher in comparison to the monomeric CPPs. For all variants, a strong accumulation 
within the nuclei could be noticed as shown in figure 8 and no significant differences 
between the internalization patterns could be seen. For instance, the cells treated with 
(sC18*)2 did not look very healthy and may have suffered from the incubation with the 
peptides. Therefore, it was investigated if the incubation of the peptides has an influence 
on the cell viability of the cells.    
 
4.1.3 Cytotoxicity profile of linear and truncated versions 
To get more insights about the influence of the peptides on cell viability and selectivity, two 
different cytotoxicity tests were performed with MCF-7 and HEK-293 cells.  
With the cell viability assay based on resazurin the viable cell number was monitored after 
incubation with the CPPs in different concentrations and compared to untreated cells. 
Therefore, cells were exposed to the non-labeled peptides in various concentrations for 
24 h and were afterwards treated with the cell permeable redox indicator resazurin. The 
viable cells with active metabolism were able to reduce resazurin into the fluorescent 
substance resorufin, which was detected using a Tecan reader at a defined wavelength. 
[78] Treatment with 70% EtOH served as positive control and untreated cells were 
measured as negative control. The results are shown in figure 9. 
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Figure 9: Cytotoxic profile of CPP variants on HEK-293 and MCF-7 cells. Cell viability of 
truncated, linear and branched variants, namely sC18, sC18*, (sC18)2, (sC18*)2, lin(sC18)2 and 
lin(sC18*)2 after incubation for 24 h with the CPPs in different concentrations, untreated cells served 
as negative control and were set to 100%. 70% EtOH was used as positive control. Experiments 
were conducted in triplicate with n = 2 (HEK-293) or n = 3 (MCF-7). Error bars represent the standard 
deviations. 
 
In general, it could be observed that all peptides were slightly more toxic to the cancer cell 
line MCF-7 than to the embryonic kidney cells. The peptides demonstrated no toxic effects 
on HEK-293 cells up to a concentration of 10 µM, whereas in MCF-7 cells, a certain toxicity 
at 5 µM could be detected in some cases. In detail, the short sequences sC18 and sC18* 
were not toxic to both cell lines and showed a very similar profile. Regarding the two 
branched variants (sC18)2 and (sC18*)2 in HEK-293 cells, also no difference could be 
noticed. In contrast, looking at the results in the cancer cells, the truncated version (sC18*)2 
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was less toxic compared to the longer version (sC18)2. This could be explained by the 
missing amino acids (IKEK in both chains, respectively) in the truncated version. Maybe, 
(sC18)2 can better interact with the plasma membrane of MCF-7 and therefore induce a 
higher cytotoxicity. Coming to answer the main question, which was, if the linear forms 
behave the same as the branched variants, the observation of the results in figure 9 showed 
that the linear derivatives are minimally more toxic to MCF-7 cells, whereby for the HEK-293 
cells, no difference could be detected. This could be proven by comparing the lin(sC18)2 
with the (sC18)2 as well as the lin(sC18*)2 with the (sC18*)2, forming the idea that the 
interruption of the two sC18 or sC18* sequences by branching leads to a reduction of 
cytotoxicity. The cytotoxic profiles of sC18 and (sC18)2 are in agreement with published 
results [77]. 
To get a better insight into the behavior of the CPPs on the cell membrane, another 
cytotoxicity assay was performed. The LDH assay is a test to estimate if substances 
permeabilize cell membranes. Lactate dehydrogenase leaks from the cytoplasm through 
the damaged cell membrane into the environmental medium. LDH converts lactate to 
pyruvate in the surrounding whereby the present resazurin is reduced to resorufin. This 
fluorescent substance can again be detected using the Tecan reader. [79] First, cells were 
treated with the different peptides in various concentrations for 1 h and afterwards incubated 
for 10 min with a mixture containing all needed substances for the reaction explained above. 
A lysis solution provided with the Kit served as positive control and was set to 100% cell 
lysis; the results of untreated cells served as negative control. The test was performed in 
triplicates and the average values are shown in figure 10 for HEK-293 and MCF-7 cells.  
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Figure 10: Membrane disruption of CPP variants on HEK-293 and MCF-7 cells. Cell lysis assay 
based on lactate dehydrogenase release after 1 h incubation with the CPPs sC18, sC18*, (sC18)2, 
(sC18*)2, lin(sC18)2 and lin(sC18*)2 in different concentrations. Cells treated with lysis solution 
served as positive control and were set to 100%, untreated cells were used as negative control and 
were subtracted from each result. Experiments were conducted in triplicate with n = 1. Error bars 
represent the standard deviations. 
 
As shown in figure 10, already at low concentrations the peptides induced cell lysis in 
MCF-7, which is quite opposite to the treatment of HEK-293 cells, whereby just some CPPs 
induce a slight cell lysis at higher concentrations. In detail, it can be concluded that the 
monomeric peptides sC18 and sC18* do not permeabilize the cell membranes of both cell 
lines. This is in consistence with previously published results [77]. For the embryonic kidney 
cells, a significant cell lysis was visible for the branched and linear peptides at a 
concentration of 25 µM, whereas about 20 to 30% of the cells were lysed. On the contrary, 
the cell lysis pattern seemed to be completely different looking at the cancer cell line MCF-7. 
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Here, the (sC18)2 started to lyse the cells at a concentration of 5 µM, whereas already 80% 
of the cells were permeabilized. At higher concentrations, the cell lysis rate even exceeded 
the ones of the positive control. As already shown in the resazurin based toxicity assay 
(figure 9), the shorter variant (sC18*)2 was a bit less toxic to the cells and their number of 
lysed cells was always a bit smaller compared to the ones of the longer parent peptide. 
Especially for 5 and 10 µM, it can be noticed that the cell lysis by the linear versions was 
triggered in higher extent, but this result was not significant except for 5 µM. It could be 
shown that the peptides (sC18)2, (sC18*)2, lin(sC18)2 and lin(sC18*)2 have a certain cell 
selectivity, because they all harmed the plasma membranes of the breast cancer cells, 
which could not be shown for HEK-293. Apart from that, the monomeric short variants sC18 
and sC18* do not have an effect on cell lysis. The membrane lysing activity of sC18 and 
(sC18)2 is in correlation with published results [77]. 
 
4.1.4 Membrane interaction studies 
The internalization and toxicity studies of the peptide variants showed differences between 
cancer and non-cancer cells. Considering the fact that the first interaction of the peptides 
with the cells is directly correlated to the composition, charge and fluidity of the cell 
membrane, which are different in cancer and non-cancer cells, studies on artificial 
membrane systems were performed. Definitely, the interaction with membrane lipids is a 
crucial step for peptide internalization. As for the longer versions (sC18)2 and lin(sC18)2, 
the highest activities on cell membrane destabilization was observed (figure 9 and 10), 
these two peptides were investigated in the following experiments. The interaction, 
destabilization and pore forming capability with different membrane systems were thereby 
tested by Mareike Horn as described in previously published studies [77]. 
Two different artificial membrane systems were generated. First, large unilamellar vesicles 
(LUVs) with a diameter of about 100 nm composed of a different lipid arrangement were 
prepared and carboxyfluorescein was enclosed in these vesicles. The CF-release could 
then be detected if the treatment with the unlabeled CPPs leads to a pore-forming or 
membrane disrupting event. The unlabeled peptides were incubated with the artificial 
membranes and the CF-release from the vesicles was determined using a plate reader. At 
the end of each experiment, Triton X-100 was applied to measure the maximum of 
dequenching, which was set to 100% and then used to normalize data. Each experiment 
was carried out three times in duplicate. Furthermore, the interaction of CF-labeled (sC18)2 
and lin(sC18)2 with giant unilamellar vesicles (GUVs), also composed of different formula 
of phospholipids, doped with 0.2 mol% Atto550-DOPE to visualize their membranes was 
investigated. The advantage of GUVs is their bigger size of 5 – 10 μm diameter, which 
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makes a microscopic observation possible. Moreover, due to their magnitude, the 
membrane curvature is comparable to that of cell membranes. [80] The interior of the GUVs 
was filled with a blue stain, namely Oyster405, to detect pore formation within the 
membranes [81, 82]. After incubating the GUVs with the CPPs, the behavior was observed 
by confocal laser scanning microscope.  
Both, the LUVs and GUVs were prepared in the following compositions: zwitterionic, non-
charged, phospholipid vesicles (made from DOPC/DOPE, 50:50) resembling the 
asymmetric distribution within electrostatically neutral mammalian membranes, which is 
simplified comparable to the cell membrane of HEK-293 cells [83, 84]. Neoplastic cells often 
comprise a more negatively charged membrane than healthy cells [85] and therefore, 
vesicles with negatively charged membranes made from DOPC, DOPG, DOPE (40:30:30) 
were investigated, too. [86, 87] To not only compare the effect of peptides on zwitterionic 
and anionic lipid membranes, the effect of different membrane fluidities was also studied by 
adding sphingomyelin and cholesterol to the latter mixture, resulting in vesicles with the 
composition DOPC/DOPG/SM/Chol (25:5:20:20). [88, 89] The results for the interaction of 
the two candidates (sC18)2 and lin(sC18)2 are depicted in figure 11.  
 
 
Figure 11: Lipid-peptide interaction studies using artificial membrane systems. (A) Peptide-
induced CF leakage experiments from LUVs composed of DOPC/DOPE (50:50), 
DOPC/DOPG/SM/Chol (25:5:20:20), DOPC/DOPE/DOPG (40:30:30) as a function of time. The 
results shown are representative of three independent preparations of LUVs. LUVs are treated with 
1 µM (sC18)2 and lin(sC18)2 for 60 min. (B) CLSM analysis of GUVs composed of DOPC/DOPE 
(50:50), DOPC/DOPG/SM/Chol (25:5:20:20), DOPC/DOPE/DOPG (40:30:30) treated with 10 µM 
(sC18)2 and lin(sC18)2 for 90 min. Red: Membrane Stain Atto550 or DiI, Green: CF-labeled peptides, 
Blue: Oyster 405. Scale bar is 30 µm. Experiments were performed by Mareike Horn. 
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Having a look on the membrane interaction studies depicted in figure 11, it is obvious that 
the behavior of the peptides with the artificial systems differed from each other depending 
on the lipid composition that was used. The zwitterionic membranes composed of the lipids 
DOPC and DOPE mimicking a neutral, non-charged phospholipid membrane were not 
interacting with the peptides. In figure 11 A, left graph, it is visible that for (sC18)2 no leakage 
of the enclosed CF in the large unilamellar vesicles could be detected, whereas for the 
linear version, a tight leakage between 5 to 10% compared to the maximum of dequenching 
could be seen. Also, no accumulation on the membrane of neutral GUVs was detectable 
(figure 11 B). The peptides seemed to stay in the surrounding environment and did not bind 
to the vesicles. Due to this, no release of the blue Oyster dye could occur. This observation 
indicates only low peptide-lipid interactions and no lytic activities of both peptide variants 
(sC18)2 and lin(sC18)2. 
On the contrary, the studies with both vesicles that are more mimicking a cancer cell 
membrane due to the negatively charged phospholipid DOPG, resulted in a completely 
different pattern. From the CF-leakage experiments with LUVs in figure 11 A, right graph, 
one can argue that the interaction with the membranes was strong and led to a fairly fast 
release of the carboxyfluorescein from the vesicles. The percentage number of leakage rate 
reached 80% within 20 min. This can occur either by forming pores within the membranes 
so that the dye can escape from the LUVs or by a complete disruption of the structures. 
Hereby, the effect is minimally more intense for the branched (sC18)2 than for the lin(sC18)2. 
These results could be confirmed observing the CLSM analysis of the GUVs consisting of 
the same lipid composition (figure 11 B right picture). For both peptides, a strong 
accumulation on the membrane and an evident release of the blue stain out of the vesicles 
could be detected. Moreover, the GUVs that were treated with (sC18)2 seemed to be smaller 
and their appearance differed from the normal round feature of a vesicle. This proved that 
the CPPs were able to interact with the negatively charged DOPG within the membranes 
and the tight interaction led to its disruption and pore formation.   
It is known, that cholesterol and sphingomyelin have an effect on membrane fluidity and 
can thereby also have an influence on the peptide-membrane interaction [89]. Thus, another 
lipid composition for the vesicle studies was chosen, namely LUVs and GUVs that are 
composed of DOPC, DOPG, sphingomyelin and cholesterol. As shown in figure 11 A, 
middle graph, the leakage rate compared to the maximum leakage using Triton-X also 
increased up to a percentage of 5 to 10% for the branched (sC18)2, whereas for the linear 
version, a leakage of 10 to 15% could be measured. One can say that the pore-forming 
events were not that present as they were for the negatively charged LUVs, but anyway a 
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certain release of the dye could be noticed. Looking at the microscopic analysis, a binding 
to the vesicles could be detected. Furthermore, one can say that a minimal amount of the 
blue Oyster stain left the vesicles, which were incubated with the branched CPP (sC18)2. 
This effect was not visible for the linear version. Notably, the dimeric peptides accumulated 
especially within the DiI-labeled disordered phases of the vesicle membranes, which are 
containing less sphingomyelin and cholesterol (Figure 11 B). Therefore, the positively 
charged CPPs presumably interacted with the anionic DOPG but the ordered phase of the 
lipid rafts in the cell membrane hinders cell membrane disruption or stronger pore-forming 
processes. Interestingly, by adding cholesterol and sphingomyelin, the strong membrane 
attack can be somehow lowered. On the one hand, this may be a consequence of the 
presence of cholesterol that has profound effects on the membrane fluidity and regulates 
also endocytosis. On the other hand, sphingomyelin together with cholesterol are reported 
to be enriched in distinct membrane domains, often referred as rafts [90].  
Apart from that, these experiments prove that the dimeric peptides play a prominent role in 
cell penetration and membrane destabilization, which is also in correlation with the 
performed toxicity assays. The higher release of the CF out of the LUVs and the blue stain 
out of the GUVs after incubation with (sC18)2 and lin(sC18)2 corresponds to the LDH release 
out of the cells tested in this study (figure 10).  
Consequently, the results showed that the CPPs were not able to overcome neutral charged 
membranes corroborating the importance of negatively charged constituents at the outer 
leaflet of the membrane. This could explain why the CPPs show a preference for the cancer 
cell line MCF-7 in internalization and cell killing. Apart from that, the addition of cholesterol 
and sphingomyelin led to a decrease of this interaction.  
In conclusion, it can be said that for (sC18)2, the highest difference between cancer and 
non-cancer cells could be shown. This was mostly visible in the cytotoxicity studies and led 
to the presumption that this variant owned the best anticancer properties. Furthermore, the 
branched peptide showed less pore-formation in the membrane vesicle studies, which 
revealed a lower cytotoxicity compared to lin(sC18)2. Therefore, this CPP was studied in 
more detail in the following part of the thesis. 
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4.2 Characterization of a CPP with potential anticancer 
activity 
In chapter 4.1, it was already shown that the branched dimeric variant (sC18)2 exhibited the 
best selectivity for cancer cells compared to the other dimeric, branched and linear versions. 
Regarding these results, this cell-penetrating peptide should be examined in more detail. 
Within all experiments, the monomeric parent peptide sC18 served as control. 
 
4.2.1 Microscopic analysis of uptake at 4 °C 
It is already known from previous studies that the uptake of sC18 occurs mainly via 
endocytosis. After internalization in HEK-293 cells, sC18 is entrapped in endosomes, which 
hinders the internalization into the nucleus. In comparison to that, the results for sC18 and 
the dimeric (sC18)2 in MCF-7 cells confirm another uptake way, namely via direct 
penetration or by endocytosis followed by a vesicle disrupting process, so that the peptides 
are then free in the cytoplasm and can internalize into the nucleus or other subcellular 
compartments. [Gronewold, master thesis 2014] [19]. To confirm this theory, a more 
detailed analysis concerning the different uptake patterns of sC18 and (sC18)2 was 
performed. The inhibition of all energy- and therefore temperature-dependent pathways like 
all the steps of endocytosis is realized by minimizing the experimental temperature to 4 °C 
[91]. So, in this study, MCF-7 and HEK-293 cells were incubated with the same 
concentration of peptide at 37 °C as well as at 4 °C. Afterwards, they were analyzed by 
fluorescence microscopy (figure 12).  
 
 
Figure 12: Uptake of CPPs at different temperatures. Fluorescence microscopy images of MCF-7 
and HEK-293 cells after 30 min incubation with 10 µM CF-sC18 or CF-(sC18)2 incubated at 4 °C or 
37 °C, respectively. Blue: Hoechst nuclear stain, Green: CF-labeled peptides, external fluorescence 
was quenched with trypan blue for 30 s, Scale bar is 10 µm. 
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The microscopic analysis of sC18 and (sC18)2 for MCF-7 and HEK-293 cells (figure 12) 
demonstrated a reduced internalization at 4 °C. This confirmed that the uptake of both CPPs 
is probably energy-dependent. Nevertheless, the effect for (sC18)2 in MCF-7 cells was not 
as strong as for HEK-293 cells, which confirmed the hypothesis that the CPPs are entering 
especially cancer cells, mainly via direct penetration. The internalization in the cancer cells 
was not affected as much as in the non-cancerous cells, when incubating at 4 °C. The same 
results could also be obtained using a peptide concentration of 1 µM (data not shown). For 
the monomeric sC18, also, a decrease in cellular uptake in MCF-7 cells could be detected. 
Hereby, one can interpret that most of the peptides entered the cells by endocytosis but 
when inhibiting this pathway, the CPP seemed to be able to overcome the membrane barrier 
also by direct penetration. In contrast to these results, the difference in the amount of 
internalized sC18 and (sC18)2 at 37 °C and 4 °C in HEK-293 cells was very high. At 4 °C, 
almost no peptides could be registered in the embryonic kidney cells. This confirmed the 
idea, that both peptides internalize HEK-293 cells mainly by endocytosis. At energy-
reduction conditions, the peptides are then not capable to internalize in visible amounts into 
the non-cancer cells.  
This result is in correlation with already published data about internalization studies in 
HEK-293 cells, which revealed that the uptake rates decrease about 80%, if the cells were 
incubated with CF-sC18 at 4 °C [19].  
 
4.2.2 Uptake studies using flow cytometry  
In order to quantify the results of the microscopic analyses, flow cytometric studies were 
performed using the same cell lines as in the above-mentioned studies (figure 13). For that, 
the cells were treated with the CPPs at different temperatures in 24-well plates and 
afterwards removed from the surface using trypsin. Then, they were analyzed in a flow 
cytometer measuring their green fluorescent signal intensity, whereby the autofluorescence 
was subtracted from each sample. 
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Figure 13: Uptake of CPPs at different temperatures. Flow cytometric analyses of cellular uptake 
of 10 µM CF-labeled sC18 and (sC18)2 in HEK-293 and MCF-7 cells incubated at 4 °C and 37 °C for 
30 min, respectively. Experiments were conducted in triplicate with n = 3, error bars represent the 
standard derivation.   
 
The flow cytometry studies shown in figure 13 confirmed the previous CLSM results, 
showing that the internalization of the dimeric (sC18)2 was about 10-times higher in relation 
to the parent monomer sC18 in the two cell lines. This effect was also detected for HEK-293 
cells, MCF-7 cells and the human colon adenocarcinoma cell line HT-29 by flow cytometric 
uptake studies investigating 10 µM peptide solutions that were incubated for 1 h [20]. 
Furthermore, the internalization rate of the dimeric peptide into MCF-7 cells is clearly higher 
than for HEK-293 cells, verifying the results of previous studies, and again demonstrating a 
potential cell selectivity of (sC18)2 [Gronewold, master thesis 2014, figure 12]. Moreover, 
when incubating MCF-7 cells at 4 °C with (sC18)2, no significant decrease in peptide 
accumulation could be observed, which confirmed the theory that the CPPs penetrated the 
cancer cells mainly by direct penetration. In contrast to this, there was a clear difference in 
the amount of internalized (sC18)2 at 37 °C and 4 °C in HEK-293 cells (*** p < 0.001) proving 
the idea that the peptides enter the non-cancer cells mainly by endocytosis, as it could also 
be shown in microscope analyses before (figure 12). 
 
4.2.3 Uptake studies with radiolabeled NODAGA-coupled peptides 
To proof the former results by other quantification techniques, radiolabeled CPP variants 
were generated. For this, a chelator had to be introduced first to the peptide sequences at 
the N-terminus, which was achieved by common coupling methods directly on solid phase. 
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Since the chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) did 
not yield sufficient complexation, and thus satisfying results concerning radiochemical 
yields, the bifunctional chelator NODAGA (4-(4,7-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7-
triazacyclononan-1-yl)-5-(tert-butoxy)-5-oxopentanoic acid) was used. In table 5, an 
overview of the NODAGA-coupled peptides is shown. 
 
Table 5: Calculated and experimentally determined molecular weights, purities and yields of 
the synthesized NODAGA-labeled peptides. For the sequences of sC18 and (sC18)2 see table 3. 
Peptide MWcalc [Da] MWexp [Da] 
Net 
charge 
Purity 
[%] 
Yield 
[%] 
NODAGA-sC18 2426.90 2427.63 + 8 > 99 ~ 60 
NODAGA-(sC18)2 4479.48 4481.25 + 16 > 95 ~ 39 
 
The chelator was successfully coupled to both sequences and the peptides were obtained 
in high purity and satisfying yields. The observed high amount of TFA salt adducts in the 
final products were removed by solving the peptides in 8 mM HCl solution. After repetitive 
lyophilization steps, the respective chloride salts were obtained.    
All following radiolabeling experiments were done in cooperation with the group of Prof. Dr. 
Schomäcker (by Sergio Muñoz Vásquez and Beate Zimmermanns) from the Institute for 
Nuclear Medicine, University Hospital, Cologne. 
The complexation of these modified peptides with the radionuclide Gallium68 worked fine 
and ended up in a radiochemical yield (RCY) above 95%. Then, the uptake experiments 
were done to see, whether the Ga68-NODAGA-peptides behave the same as the CF-labeled 
ones. HEK-293 and MCF-7 cells were incubated with really low concentrations of 
0.823 nmol of Ga68-NODAGA-peptides. The radioactivity was measured in a gamma 
spectrometer and the results are illustrated in figure 14. 
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Figure 14: Cellular uptake of 68Ga-NODAGA-modified peptides measured in a gamma 
spectroscopy system. Relative uptake of 0.0823 nmol 68Ga-NODAGA-modified sC18 or 68Ga-
NODAGA-modified (sC18)2 in HEK-293 and MCF-7 cells, respectively. The results are represented 
in relative amounts of internalized peptide, error bars represent the standard derivation. 
 
Figure 14 shows that the CPPs are still able to internalize into both cell lines, when 
incubating the cells with very low peptide concentrations of 0.823 nmol. Additionally, when 
adding Ga68-NODAGA-peptides at these concentrations, the uptake in both cell lines for 
both peptides is not significantly different. This is in contrast to the results obtained using 
higher concentrations. It was published by Guterstam et al. that the uptake of cell-
penetrating peptides is highly depending on various factors. Within this the dependence of 
CPP concentration is often mentioned. [26] For sC18 and (sC18)2, it could be shown that 
the different uptake rates in cancer and non-cancer cells occurred with concentration in the 
micromolar range, but not at lower peptide amounts.  
 
4.2.4 Tracking the intracellular fate of the CPPs after cellular 
uptake 
Next, it should be elucidated where the peptides remain over time after incubation with the 
cells. It is interesting to verify if the peptides would leave the cells over time or are degraded 
or if they stay inside and accumulate in certain compartments. Therefore, HEK-293 and 
MCF-7 cells were incubated with 10 µM of sC18 and (sC18)2 for 30 min. Afterwards, the 
solutions were removed, the cells were washed and then incubated for 6 h in the appropriate 
medium containing serum. In figure 15, the results at the time points ‘t = 30 min + 0’ and 
‘t = 30 min + 6 h’ are shown.   
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Figure 15: Observation of peptides 6 h after incubation. Fluorescence microscopy images of 
MCF-7 and HEK-293 cells after 30 min incubation with 10 µM CF-sC18 or CF-(sC18)2 and 
observation just afterwards or after 6 h in peptide-free medium, respectively. Blue: Hoechst nuclear 
stain, Green: CF-labeled peptides, external fluorescence was quenched with trypan blue for 30 s, 
Scale bar is 10 µm. 
 
When comparing the pictures in figure 15, it was visible, that the peptides differed in their 
internalization pattern depending on the observed cell line. In HEK-293 cells, the amount of 
peptides, as well as its destination inside the cells (e.g. vesicles) was more or less equal 
after 6 h. These results are in line with the theory that the uptake in these cells occurs via 
endocytosis (chapter 4.2.1 and 4.2.2). Thereby, the peptides remained encapsulated in the 
vesicles and were not released into the cytosol. The endosomes are then undergoing the 
degradative pathway and will be developed to endolysosomes [92]. The lysosomes contain, 
among other enzymes, hydrolases to degrade the peptides enzymatically [93]. These 
lysosomes are visually not distinguishable from endosomes. 
On the contrary, in MCF-7 cells, a difference between the time points 0 and 6 was obvious. 
The amount of sC18 was lower after 6 h and just visible in fluorescent dots, presenting the 
peptides encapsulated in vesicles. Probably, most of the CPPs that entered the cells by 
endocytosis was released from the vesicles and could then be degraded in the cytosol. 
Thus, after 6 h, there were just a few amount of peptide left in the lysosomal pathway. After 
endosomal release, the free CPPs within the cytoplasm were either degraded by cytosolic 
enzymes or transported out of the cells. Also for (sC18)2, whereof almost no peptide was 
left after 6 h, it can be assumed, that it got degraded within the cytoplasm or also released 
in the surrounding medium. These results are confirming the idea that the internalization in 
MCF-7 cells happened mainly via direct penetration. 
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4.2.5 Triggering endosomal release in HEK-293 cells   
As previously shown, the cell-penetrating peptides sC18 and (sC18)2 seemed to internalize 
in the embryonic kidney cells HEK-293 via endocytosis, but staying then encapsulated 
within the vesicles and not being therefore able to enter the cell nucleus. To examine this 
hypothesis further, the disruption of the membrane and thus the endosomal release of the 
peptides in the cytoplasm should be triggered in various ways. For instance, it is possible 
to use multivalent CPPs, pH-dependent membrane active peptides (PMAPs) and 
endosomal escape sequence motifs like GALA, KLA or KALA. Also longer peptides as e.g. 
melittin (26 amino acids) derived from the bee venom can trigger endosomal release by 
pore-formation [3]. Furthermore, photochemical lysis of the endosomes, or the use of 
chemicals like CaCl2, chloroquine or sucrose can trigger the disruption of vesicles. [15, 94-
96] In this study, the improvement of endosomal release of CPPs was triggered with the 
chemicals chloroquine, sucrose and CaCl2. Chloroquine (CQ) is a lysosomotropic base, 
which accumulates in vesicles and can thereby inhibit the acidification of the endosomes, 
preventing a development to endolysosomes. Furthermore, due to the accumulated ions, 
the CQ promotes swelling and disruption of the vesicles. [28, 97] This effect could also be 
shown for sucrose. The sugar accumulates in the endosomes and leads to swelling as well 
as destabilization, resulting in a release of the vesicle content into the cytosol. [98, 99]. 
Calcium is attributed to disorder membranes during peptide entry and can therefore trigger 
the uptake [100, 101]. 
The cells were incubated for 30 min with 10 µM of the CPPs sC18 and (sC18)2, respectively 
and the three mentioned agents were added. The pictures after microscopically observation 
are shown in figures 16 and 17.  
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Figure 16: Localization of sC18 after endosomal disruption. Fluorescence microscopy images 
of HEK-293 cells after 30 min incubation with 10 µM CF-sC18 and additionally 100 µM chloroquine, 
6 mM CaCl2 or 0.5 M sucrose, respectively. Blue: Hoechst nuclear stain, Green: CF-labeled peptides, 
external fluorescence was quenched with trypan blue for 30 s, Scale bar is 10 µm. 
 
Cells treated with 100 µM chloroquine or 6 mM CaCl2 in addition to the peptide sC18, did 
not show a major difference in peptide distribution within the cells compared to the control. 
In contrast to that, the cells that were incubated with 0.5 M sucrose in addition to the peptide 
showed a cytosolic distribution with an especially high accumulation in the nuclei. In those 
cells, the sucrose seemed to successfully induce the release of the peptides into the cytosol.  
 
 
Figure 17: Localization of (sC18)2 after endosomal disruption. Fluorescence microscopy images 
of HEK-293 cells after 30 min incubation with 10 µM CF-(sC18)2 and additionally 100 µM chloroquine, 
6 mM CaCl2 or 0.5 M sucrose, respectively. Blue: Hoechst nuclear stain, Green: CF-labeled peptides, 
external fluorescence was quenched with trypan blue for 30 s, Scale bar is 10 µm. 
 
For (sC18)2 somehow different results were obtained. Figure 17 shows that the incubation 
with all tested substances led to a different distribution and localization of (sC18)2 in 
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HEK-293 cells. The microscopic pictures of the cells treated with CQ and CaCl2 display 
some cells, where the CPPs were also distributed in the cytoplasm, shown by a diffuse 
green signal – as well as in the nuclei. This effect was even stronger when incubating the 
cells with 0.5 M sucrose. Hereby, almost all cells could be observed in the previously 
described phenotype. The cell nuclei appeared as normal, indicating no toxic effects 
induced by the agents. 
The differences between the two investigated CPPs correlated well with the expectations, 
since the uptake rate of the dimer at this concentration was about 10-fold higher than that 
of the monomer, which was already demonstrated in chapter 4.2.2. Thus, the amount of 
sC18 in the endosomes was less than (sC18)2 and a disruption of the vesicles, filled with 
the monomeric peptide, did not lead to detectable amounts of CF in the cells.   
To underline the hypothesis, that the increase of the green signal did not occur because of 
the toxic effects induced by the chemicals, cytotoxic tests were performed. The results are 
shown in figure 18.  
 
 
Figure 18: Toxicity profile of endosomal release triggering substances (A) Cell viability assay 
based on resazurin of 10 µM (sC18)2 alone or co-incubated with 6 mM CaCl2, 100 µM CQ or 0.5 M 
sucrose, respectively, on HEK-293 cells after incubation for 1 h, untreated cells served as negative 
control and were set to 100%. 70% EtOH was used as positive control. (B) Cell lysis assay based 
on lactate dehydrogenase release after 1 h incubation of HEK-293 cells with 10 µM (sC18)2 alone or 
co-incubated with 6 mM CaCl2, 100 µM CQ or 0.5 M sucrose, respectively. Cells treated with lysis 
solution served as positive control and were set to 100%, untreated cells were used as negative 
control and were subtracted from each result. Both experiments were conducted in triplicate with 
n = 1. Error bars represent the standard deviations. 
 
The cytotoxicity profile in figure 18 demonstrates that none of the tested substances 
exhibited any cytotoxic effects in the used concentrations. No decrease in cell viability could 
be observed (figure 18 A) and just a minimal cell lysis could be detected for the treatment 
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with CQ (figure 18 B). Despite the fact that these experiments were performed only once, 
the tendency is supporting the idea that the chemicals did not harm the cells. Therefore, the 
distribution of the CPPs in figures 16 and 17 were a consequence of the triggered 
endosomal release.  
The endosomal uptake of sC18 and (sC18)2 in HEK-293 cells could be proved by these 
results. Thereafter, the peptides remained, without any endosomal releasing effect, 
encapsulated in the vesicles and were not able to penetrate the nuclei as well as other 
compartments. Furthermore, one can say that an improvement in the application especially 
of the dimeric peptide could be obtained by adding certain substances as CaCl2, 
chloroquine and sucrose. 
 
4.2.6 Relevance of membrane composition 
From the previous experiments, a certain cell selectivity was observed for the peptides sC18 
and (sC18)2 which was in agreement to former results [19, 20, 77]. To confirm the theory, 
that this selectivity and therefore a better internalization into the negatively charged cancer 
cells, is correlated with the lipid composition of the membranes, both peptides were also 
examined on artificial membrane-like systems. The following experiments were established 
and performed by Mareike Horn. As described above (chapter 4.1.4), the CPPs were tested 
with giant and large unilamellar vesicles, composed of different lipid formula, that contained 
an encapsulated dye. The accumulation on the membrane and pore formation in the 
vesicles could be observed. [77, 81] The results are presented in figure 19.  
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Figure 19: Lipid-peptide interaction studies using artificial membrane systems. (A) Peptide-
induced CF leakage experiments from LUVs composed of DOPC/DOPE (50:50), 
DOPC/DOPG/SM/Chol (25:5:20:20), DOPC/DOPE/DOPG (40:30:30) as a function of time. The 
results shown are representative of three independent preparations of LUVs. LUVs are treated with 
1 µM sC18 and (sC18)2 for 20 or 60 min. (B) CLSM analysis of GUVs composed of DOPC/DOPE 
(50:50), DOPC/DOPG/SM/Chol (25:5:20:20), DOPC/DOPE/DOPG (40:30:30) treated with 10 µM 
sC18 and (sC18)2 for 90 min. Red: Membrane Stain Atto550 or DiI, Green: CF-labeled peptides and 
Blue: Oyster 405. Scale bar is 30 µm. Experiments were done by Mareike Horn. 
 
The interaction of both CF-labeled peptides with neutrally charged GUVs was negligible 
after an incubation time of about 90 min, and no green fluorescent signal was observed on 
the vesicle membrane as well as no intravesicular blue stain escaped out of the vesicles 
(figure 19 B left). Also the incubation with the CF-filled LUVs did not show any release of 
the fluorescent dye from the vesicles (figure 19 A left). This observation indicates a low 
peptide-lipid interaction and no lytic activities of both peptide variants. 
In contrast, the experiments with negatively charged GUVs, that mimic a cancer cell 
membrane (figure 19 B right), showed an accumulation of the monomeric peptide sC18 on 
the artificial membrane and a slight release of the blue fluorescent stain Oyster 405. 
Regarding the experiments with LUVs, one could detect a release of the CF from the 
vesicles about 10%. For the dimeric peptide (sC18)2, next to the strong accumulation on 
the GUV membrane, a higher release of the blue stain out of the vesicles could be detected. 
Moreover, the appearance of the GUV differed from the normal feature of a vesicle, 
indicating a disrupting event on the lipid membrane. This effect was similar to the well-
studied cell-penetrating peptide transportan for which membrane lytic activity has been 
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already described [102]. This peptide as well as its shorter variant TP10 showed high 
potential in delivering various cargoes into cells [21, 52]. It is possible that the internalization 
and the transport capacities of (sC18)2 are comparable to these well studied CPPs. Looking 
at the results of the experiments with the LUVs containing DOPG in the right graph in figure 
19 A, it is visible, that the interactions are the same as observed with the giant unilamellar 
vesicles. The incubation with sC18 led to a slight release of CF about 10% after 60 min 
whereas the release of the dye when incubating the vesicles with (sC18)2 occurred very fast 
at a percentage of 90%. This effect could either take place due to pore-forming events within 
the vesicle membranes so that the dye could leak from the LUVs, or by a complete 
disruption of the structures. 
Next, the vesicles composed of DOPC, DOPG, sphingomyelin and cholesterol should be 
elucidated. As described before, cholesterol and sphingomyelin have an influence on the 
peptide-membrane interaction (chapter 4.1.4) [89]. In figure 19 B in the middle picture, it is 
illustrated, that sC18 did not accumulate on the GUV membrane. Also in the LUV 
experiment, no release of carboxyfluorescein from the vesicles could be measured. For the 
dimeric peptide, an accumulation on the vesicle membrane was visible, but the binding was 
not that strong as it could be observed for the negatively charged GUVs without cholesterol 
and sphingomyelin. Also a release of the blue dye was hardly detectable. Furthermore, the 
leakage rate from the large unilamellar vesicles compared to the maximum leakage using 
Triton-X, which is completely disrupting the membrane, increased up to a percentage of 
about 8%, which was considerably less than in the LUVs composed of 
DOPC/DOPE/DOPG.  
Consequently, the results showed that the CPPs were not able to overcome neutrally 
charged membranes corroborating the importance of negatively charged constituents in the 
outer leaflet of the membrane. In general, this could explain the fact that the CPPs showed 
a preference for the cancer cell line MCF-7 in internalization and cell toxicity compared to 
the non-cancer cell line HEK-293. It is likely that the positively charged CPPs interacted 
with the anionic DOPG, which led to pore-forming events. These experiments were in 
coincidence with the previously presented lytic activity of (sC18)2 on MCF-7 cells (figure 10). 
Anyway, sphingomyelin and cholesterol in the cell membrane seems to hinder the cell 
membrane disruption.  
To prove the idea, that cholesterol hinders the interaction of (sC18)2 with the cell membrane, 
a cholesterol depletion assay was performed using methyl-β-cyclodextrin (MβCD). 
Afterwards, the cells were incubated with the peptides as usual and then observed by 
microscopy or flow cytometry. In figure 20, the results for the cancer cell line MCF-7 are 
presented.  
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Figure 20: Treatment of MCF-7 cells after cholesterol depletion. (A) Fluorescence microscopy 
images of MCF-7 incubated with 5 µM CF-sC18 or 1 µM CF-(sC18)2 for 30 min alone or after 
cholesterol depletion using 10 mM methyl-ß-cyclodextrin for 1 h. Blue: Hoechst nuclear stain, Green: 
CF-labeled peptides, external fluorescence was quenched with trypan blue for 30 s, Scale bar is 
10 µm (B) Flow cytometric analyses of cellular uptake of CF-labeled peptides sC18 and (sC18)2 in 
MCF-7 cells incubated at 37 °C for 30 min with or without earlier cholesterol depletion. Experiments 
were performed in triplicate with n = 3. Experiments were done by Mareike Horn. 
 
It is obvious in both experimental setups that the internalization and intracellular distribution 
of the monomer was not harmed by cholesterol depletion. This verified the observation, 
which was shown with the LUVs and GUVs experiments in figure 19, namely that the 
cholesterol in the membrane was not that important for the sC18 membrane interaction. In 
the contrary, the internalization rate of the dimeric (sC18)2 was extremely decreased when 
cholesterol was sequestered from the membranes of MCF-7 cells. In the flow cytometric 
observations, a significance level of <0.001 could be detected. Furthermore, the peptides 
just accumulated in the nuclei and almost no green signal could be observed in the 
cytoplasm of the cells. In addition, the same experiment was performed with HEK-293 cells 
and similar results could be obtained (data not shown).  
It was published previously, that cholesterol depletion inhibits the uptake of a TAT-Cre 
protein [103]. Furthermore, it is known that the removal of cholesterol disturbs some lipid 
raft–mediated endocytic pathways like macropinocytosis and caveolae dependent 
endocytosis. Because the uptake of (sC18)2 was highly reduced after the removal of 
cholesterol, one could assume that the peptide was penetrating cells via lipid raft–mediated 
endocytosis. [104, 105] 
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Anyway, taking these studies in consideration, the highly potent cell selectivity for cancer 
cells of (sC18)2 is depending on the composition of the target membrane. 
 
4.2.7 Uptake and cytotoxicity screening on various cell lines 
To further study a potent cancer selectivity of (sC18)2, several other cell lines, namely 
HCT-15, HeLa, PC-3, a human prostate cancer cell line [106], and the keratinocyte cell line 
from adult human skin HaCaT [107] were investigated concerning the cellular uptake and 
toxicity of sC18 and (sC18)2. Some of them were already used in previous studies 
[Gronewold, master thesis 2014]. As reference, HEK-293 and MCF-7 cells are again 
included. In figure 21, the microscopic results for all examined cell lines are shown.  
  
 
Figure 21: Uptake of sC18 and (sC18)2 in various cell lines. Fluorescence microscopy images of 
HEK-293, HaCaT, MCF-7, PC-3, HeLa and HCT-15 cells after 30 min incubation with 10 µM 
CF-sC18 and CF-(sC18)2, respectively. Blue: Hoechst nuclear stain, Green: CF-labeled peptides, 
external fluorescence was quenched with trypan blue for 30 s, Scale bar is 10 µm. 
 
For all inspected cell lines, it could be detected that after treatment with the dimeric peptide 
(sC18)2 the intracellular fluorescence intensity was higher than after treating the cells with 
the linear peptide sC18. The overall punctuate distribution indicated that the peptides 
entered the cells mainly by endocytosis. 
From the microscope pictures of HaCaT cells, showing both peptides with a diffuse and 
punctuate distribution inside the cytoplasm, as well as accumulation in the cell nucleoli, one 
can assume that the internalization pattern was different from the one of HEK-293 cells. 
Hereby, the peptides seemed to enter the cells the same way, they did for MCF-7 cells. The 
punctual distribution portends an endocytotic way of cell penetration but the diffuse green 
signal might also be an evidence for direct penetration, or for release of the peptide out of 
endocytic vesicles [27]. In general, it could be shown, that the previously described cell 
selectivity for cancer cells is possibly also applicable for keratinocytes.   
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Having a look at PC-3 cells, one can see that there was a slight increase in uptake of the 
dimer compared to the monomer. The fluorescent signal for both peptides could be detected 
as punctuate distribution in the cytoplasm, which is an indicator for endosomal uptake. 
Furthermore, for (sC18)2 a diffuse signal could also be observed within the cytoplasm, 
indicating either a direct penetration above the cell membrane or an endosomal uptake with 
following release from the vesicles. [27] Moreover, the dimeric peptide was also able to 
cross the cell nuclei membrane and accumulate in the nucleoli, whereas for the monomer 
only minor uptake into the nuclei was observed. 
Regarding the HeLa cells, the fluorescent signal for sC18 could be detected as punctual in 
the cytoplasm and for (sC18)2 the pictures indicate that the peptide accumulated in the 
cytoplasm and in the nucleoli as for MCF-7 cells.  
For the cell line HCT-15 the gain of the green signal was adjusted to the fluorescence 
intensity of the dimer. Hence, there was no green signal in the microscope pictures of the 
monomer. Notably, the fluorescent labeled (sC18)2 peptide was not present in every cell, 
and in cells, where the peptide was detectable, the signal was present in the cytoplasm as 
well as in the nuclei. Certainly, the monomer is also entering the HCT-15 cells, but due to 
the low gain value that was chosen at this time there was no green signal detectable.  
These results confirm the differences between the monomeric peptide sC18 and the dimeric 
peptide (sC18)2, as well as discrepancies in their internalization patterns in different cell 
lines and a therefore clear detectable selectivity for cancer cells as well as for the epithelial 
cell line HaCaT. This effect is certainly connected to the different constitutions of the cellular 
membranes and could be shown for many other cell-penetrating peptides before [83, 108]. 
It was also very conspicuous that the dimeric peptide (sC18)2 was often localized within the 
nucleoli when penetrating the cell nuclei. This could be explained by the high amount of 
ribosomes in the nucleoli. Here, the ribosomes are generated, which are needed for the 
biosynthesis of proteins in translation afterwards. Ribosomes are composed of ribonucleic 
acids and proteins. Furthermore, many non-nuclear proteins are present in the nucleoli 
[109]. This high content of proteins in these cell nuclear regions could be the reason why 
the cell-penetrating peptides accumulate here, due to an interaction and attraction of the 
amino acid residues of the CPPs to the proteins present in the nucleoli. 
As the variety of the internalization and localization of the CPPs is certainly connected with 
the membrane constitution of the cells, it is likely that the peptides also have different 
cytotoxic effects. This should also be investigated on the cell lines used in this thesis. The 
results of the cell viability assays are presented in figure 22. The results of HEK-293, MCF-7, 
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HeLa and HCT-15 cells were partly taken from previous studies [Gronewold, master thesis 
2014]. 
 
 
Figure 22: Cytotoxic profile of sC18 and (sC18)2 tested on various cell lines. Cell viability assay 
on HEK-293, HaCaT, MCF-7, PC-3, HeLa and HCT-15 cells after incubation for 24 h with sC18 or 
(sC18)2 in various concentrations, untreated cells served as negative control, cells treated for 10 min 
with 70% EtOH were used as positive control and subtracted from each measurement, experiments 
were conducted in triplicate with n = 3 (HEK-293, HaCaT, MCF-7, HeLa and HCT-15) and n = 1 
(PC-3), Error bars represent the standard derivation.  
 
As for all observed cell lines, the monomer sC18 did not show any toxicity in the used 
concentrations, independently if the CPP was incubated with non-cancer or cancer cells. 
The relative cell viability of all cell lines stayed around 100% using concentrations up to 
100 µM. These examinations are in line with published results [19]. Here, the cell lines HeLa 
and MCF-7 were tested with the monomeric sC18 in the resazurin based assay, using 
concentrations of 10 and 100 µM, respectively, and no significant difference to untreated 
cells could be detected. In the present study, only for the keratinocytes HaCaT, a decrease 
of cell viability to 75% at a concentration of 100 µM could be seen.  
In contrast, after the incubation with the peptide (sC18)2, the relative cell viability decreased 
with higher concentration of peptide in all cell lines. In HEK-293 cells, the CPP was not toxic 
up to a concentration of 10 µM, whereas at 50 µM only about 35% of the cells were still 
viable and all cells were dead at the highest tested concentration of 100 µM. Observing the 
results of the keratinocytes, one could see that (sC18)2 had no toxic effect on the cells 
except from a decrease of viable cells to about 85% when incubating with 100 µM peptide 
solution. As shown for MCF-7 cells before (chapter 4.1.3), the dimer was slightly toxic at 
10 µM (75% cell viability) and at concentrations higher than 25 µM, almost no viable cells 
could be detected. The human prostate cancer cell line PC-3 was not affected by the cell-
penetrating peptide up to a concentration of 50 µM. At 100 µM, about 15% of viable cells 
remained. For HeLa cells, more or less the same outcome than for MCF-7 cells could be 
noted and the experimental data of HCT-15 cells resembled the ones of HEK-293.   
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Looking at all examined results for the dimeric CPP (sC18)2, a gradient of cytotoxicity effect 
on the observed cell lines in the range of 10 – 100 µM can be concluded. The CPP is not 
toxic to HaCaT cells, slightly toxic to PC-3 cells, followed by HCT-15 and the embryonic 
kidney cells. The highest toxicity could be observed for the cancer cell lines MCF-7 and 
HeLa. 
To further observe the efficacy of (sC18)2, Ivan Ranđelović of the group of Dr. József Tóvári 
in Budapest analyzed 16 cancer cell lines (melanoma, liver, pancreas, breast, lung, oral, 
fibrosarcoma and colon cancer) as well as one human fibroblast cell line using an MTT cell 
viability assay. The IC50 values are shown in table 6.  
 
Table 6: IC50 values when incubating (sC18)2 with different cell lines. Toxicity was determined 
with the MTT assay by Ivan Ranđelović in Budapest as described in Gronewold et al. 2017. [77] 
Cell line  IC50 [µM] 
Melanoma A2058 3.9 ± 0,8 
 HT168-M1/9 9.2 ± 0,3 
 M24 16.2 ± 9,8 
Liver HepG2 5.4 ± 0,1 
Prostate PC-3 8.8 ± 1,4 
 DU145 12.3 ± 1,3 
Pancreas Panc-1 23.2 ± 5,0 
Breast MDA-MB-231 30.9 ± 1,2 
 MCF-7 6.2 ± 1,0 
Lung A549 27.3 ± 2,0 
 H1975 6.5 ± 0,1 
 H1650 4.5 ± 0,3 
Oral (head and neck) PE/CA-PJ15 39.6 ± 4,5 
 PE/CA-PJ41 36.2 ± 1,1 
Fibrosarcoma HT1080 7.4 ± 0,6 
Colon HT-29 9.5 ± 0,3 
Normal fibroblasts MRC-5 >50 
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Considering the IC50 values depicted in table 6, it is shown that (sC18)2 was again more 
active against almost all cancer cell lines and the fibroblast cell line was significantly less 
affected in comparison with an IC50 value above 50 µM. The highest cytotoxic effect of the 
peptide could be examined against the melanoma cell line A2058, the liver cells HepG2, 
the well-studied breast cancer cell line MCF-7, and the lung cancer cells H1975 and H1650 
with averaged IC50 values underneath 7 µM. The results for MCF-7 are in line with the ones 
shown in the previous cell viability assay in figure 22. The estimated IC50 value of HCT-15 
cells in the previous tests was about 25 µM. The herein tested colon cancer cells HT-29 are 
with a value of 9.5 in more or less the same range. For the prostate cancer cell line PC-3, 
another outcome of the cytotoxicity was observed. The experiments with PC-3 cells done 
in this study (figure 22) were just performed once, so this should be taken with caution.  
In conclusion, it could be shown that the dimerization of the linear peptide sC18, which 
contains a higher number of positive charges, leads to a higher cytotoxicity in a wide range 
of cells. Overall, the results let assume a high therapeutic potency of (sC18)2 for several 
cancer models.  
 
4.2.8 Cargo delivery of actinomycin D  
Finally, studies on the delivery features were performed to demonstrate that (sC18)2 could 
serve as a good cellular delivery vector for scientific and therapeutic purposes. Hoyer et al. 
showed in 2012 that (sC18)2 exhibits this property. The covalent binding of two cytostatic 
agents, precisely a functionalized cymantrene and the anticancer therapeutic chlorambucil, 
to the peptide led to a significant reduction of cell viability in the cancer cell lines HT-29 and 
MCF-7 compared to the respective sC18 conjugate and the unconjugated cytostatic 
compounds. [110] 
In this study, it should be elucidated, if sC18 and (sC18)2 are also able to transport 
non-covalently attached cargo within MCF-7 cells, because the covalent coupling of drugs 
is of course highly laborious and time-consuming. The antitumor antibiotic actinomycin D, 
which was used in this experiment, can intercalate with DNA and inhibit the RNA synthesis 
[111]. As for (sC18)2 a lytic effect on the cell membrane could be shown (figure 10), it is 
possible that a co-incubation with the antibiotic is sufficient for the transport and successful 
targeting of the drug into the cells and to the DNA. For this investigation, cells were exposed 
to the peptides sC18 and (sC18)2 alone, actinomycin D alone and the co-incubated 
peptide/actinomycin D solution for 24 h. Afterwards a cell viability assay was done to detect 
the number of viable cells. Therefore, a concentration of actinomycin D was determined 
before (data not shown), whereby the cells are not affected, so that a toxic effect should be 
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directly correlated with the transport ability of the CPPs. The results are presented in 
figure 23. 
 
 
Figure 23: Cargo delivery of actinomycin D in MCF-7 cells. Cytotoxicity assay based on resazurin 
after incubation with 0.1 µM actinomycin D, 10 µM sC18 or 10 µM (sC18)2 alone or co-incubated with 
actinomycin D (0.1 µM) for 24 h. Untreated cells served as negative control, cells treated for 10 min 
with 70% EtOH as positive control and were subtracted from each result. Experiments were 
conducted in triplicate with n = 2, error bars represent the standard derivation. 
 
The results in figure 23 show, that 0.1 µM actinomycin and 10 µM sC18 alone are not toxic 
to the cancer cells. Also the combination of the drug and the monomeric CPP did not lead 
to a significant toxic effect. Due to the uptake by endocytosis and no lytic activity, the 
monomeric peptide sC18 was expected not to be able to efficiently trigger the transport of 
the drug to the DNA, which could be confirmed in this experiment. Even when the CPP 
could carry the actinomycin D into the cells via endocytosis, the two compounds might stay 
enclosed in the vesicles and therefore the agent cannot enter the cell nuclei and fulfil its 
function.     
However, the incubation with (sC18)2 indicated a high decrease of viable cells to around 
70% which is in agreement with the results in figure 22. When co-incubating the CPP with 
the anticancer antibiotic, the cell viability decreases further to about 30%. This indicates 
that the dimeric CPP was triggering the uptake of actinomycin D into the cells with a 
significant p-value less than 0.01. The difference between the co-incubation with the 
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monomer and the dimer was even more defined with a significance level of <0.001. Taking 
all this in consideration, it seemed that the interaction of (sC18)2 with the negatively charged 
cancer cell membrane led to pore-forming events and this facilitates the entry of the drug. 
Actinomycin D was than unbound in the cytosol, could overcome the nuclear membrane 
and intercalate with the DNA, which led to the inhibition of RNA synthesis and in the end to 
cell death.  
From the detailed observation of (sC18)2, one can conclude that this peptide possesses 
potential cancer selectivity to many different kind of cancer cells and showed membrane 
disrupting properties. Furthermore, it was also able to transport a cytotoxic drug efficiently 
into MCF-7 cells.   
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4.3 Specific targeting of nuclei and nucleoli using modified 
CPPs 
Within this study, it was tried to create a set of new chimeric CPPs that specifically target 
the cell nuclei, and act as delivery vectors, potentially even better as the already described 
branched (sC18)2. For a targeted delivery to the nuclei, the truncated cell-penetrating 
peptide sC18* was combined with the nuclear localization sequence N50 or the nucleoli-
targeting peptide NrTP, respectively. N50 is a nuclear localization sequence of the 
NFκB1/p50 subunit and NrTP is derived from a toxin sequence [35, 65]. A fusion of NrTP 
and N50 to CPPs is not published until now.   
 
4.3.1 Peptide synthesis and analysis of the secondary structure 
All peptides were synthesized via solid-phase peptide synthesis as previously described. 
Moreover, unlabeled and carboxyfluorescein-labeled versions were generated. After 
cleavage from the resin and purification, all peptides were analyzed by HPLC/ESI-MS. The 
results are shown in table 7.  
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Table 7: Sequences, calculated and experimentally determined molecular weights, purities and yields of the synthesized peptides, unlabeled and labeled 
with carboxyfluorescein (CF). The data for sC18* and CF-sC18* can be found in table 3. 
Peptide Sequence MWcalc [Da] MWexp [Da] 
Net 
charge 
Purity [%] Yield [%] 
N50 VQRKRQKLMP-NH2 1282.61 1282.76 + 5 > 99 ~ 81 
CF-N50 CF-VQRKRQKLMP-NH2 1640.93 1641.11 + 4 > 93 ~ 55 
N50-sC18* VQRKRQKLMPGLRKRLRKFRNK-NH2 2836.51 2837.20 + 12 > 99 ~ 93 
CF-N50-sC18* CF-VQRKRQKLMPGLRKRLRKFRNK-NH2 3194.83 3195.65 + 11 > 97 ~ 54 
NrTP YKQCHKKGGKKGSG-NH2 1504.76 1505.03 + 6 > 99 ~ 59 
CF-NrTP CF-YKQCHKKGGKKGSG-NH2 1863.08 1863.53 + 5 > 99 ~ 57 
NrTP-sC18* YKQCHKKGGKKGSGGLRKRLRKFRNK-NH2 3058.67 3059.31 + 13 > 99 ~ 82 
CF-NrTP-sC18* CF-YKQCHKKGGKKGSGGLRKRLRKFRNK-NH2 3416.99 3417.69 + 12 > 99 ~ 33 
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As can be depicted in table 7, all peptides could be successfully synthesized and moreover, 
high purities and yields could be obtained.  
For structural characterization of the synthesized peptides, a CD spectrum was recorded with 
the unlabeled peptides. The peptides were diluted to a concentration of 20 µM in phosphate 
buffer (pH 7) with or without TFE, respectively, and measured in the CD spectrometer. The 
spectra are shown in figure 24. 
 
 
Figure 24: Secondary structure analysis of CPP variants. Circular dichroism spectra of the 
investigated peptides N50, N50-sC18*, NrTP and NrTP-sC18*. Peptides were measured in a 
concentration of 20 µM in 10 mM phosphate buffer (pH 7) with (B) and without (A) 50%-trifluoroethanol 
(TFE) (n = 1). 
 
Judged by the observation of figure 24 A, all peptides exhibited a random coil structure in 
phosphate buffer without TFE. In the presence of the secondary structure inducing solvent 
trifluoroethanol [112], the peptides N50 and NrTP also exhibited a random coil structure. On 
the contrary, in buffer with TFE, for N50-sC18* and NrTP-sC18* the formation of α-helices 
could be determined (figure 24 B). This was also affirmed by the calculated R-values, which 
were 0.83 for N50-sC18* and 0.70 for NrTP-sC18*. This proves that the combination of the 
nuclei-targeting sequences with the CPP sC18* led to the formation of an α-helical structure, 
whereas the nuclei and nucleoli targeting sequences alone were not able to do so. As depicted 
in figure 7, sC18* alone is also exhibiting an α-helical character, which was also published 
recently [73]. 
 
4.3.2 Internalization rates of nuclei-targeting sequences  
To get a first hint about the internalization features of the new CPP variants, the uptake into 
two cancer cell lines, namely MCF-7 [113] and HeLa [114], was investigated using flow 
cytometric analysis. Therefore, cells were treated with CF-labeled peptides, detached and then 
analyzed in the flow cytometer. The results for both cell lines are shown in figure 25. 
Results and Discussion 
 
66 
 
Figure 25: Uptake studies with CPP variants. Flow cytometric analyses of cellular uptake of 10 µM 
CF-labeled peptides sC18*, N50, N50-sC18*, NrTP and NrTP-sC18* in MCF-7 and HeLa cells incubated 
at 4 °C and 37 °C for 30 min, respectively. 10’000 events were analyzed, untreated cells served as 
negative control, experiments were conducted in triplicate with n = 3 (HeLa) or n = 2 (MCF-7). Error bars 
present the standard derivation.   
 
Surprisingly, both new CPP variants, N50-sC18* and NrTP-sC18*, entered the cells extremely 
efficiently with much higher uptake rates compared to the CPP sC18* alone. In fact, it must be 
considered that the intensities of N50-sC18* and NrTP-sC18* were such high, that the 
increased fluorescent signal was diminished with the aim to still measure all signals. Therefore, 
the internalization of sC18* seemed to be very low. Anyway, the measured signals for the NLS-
sequence N50 and the nucleoli-targeting sequence NrTP alone were that minor that one 
cannot assume any internalization ability for these peptides from these experiments. 
Rádis-Baptista et al. showed that rhodamine B-labeled NrTP can enter into three different 
tumor cell lines (human ductal mammary gland carcinoma (BT-474), human pancreatic 
adenocarcinoma (Bx-PC3) and murine neuroblastome (N2A) cells) at a concentration of 50 µM 
after incubation for 45 min [35]. In this present study, a concentration of 10 µM was used for 
30 min; therefore the cell-penetrating capability of the NrTP sequence can probably be 
increased by augmenting the concentration. Another study also claimed very low 
cell-penetrating properties for N50 at a concentration of 10 µM in 4 different cell lines (African 
green monkey kidney (Cos-7), human embryonal kidney (HEK-293), human cervix carcinoma 
(HeLa) and Madin-Darby canine kidney (MDCK)) [115]. However, the fusion of the NLS and 
NrTP sequences with sC18* resulted in uptake rates that were much higher compared to the 
sC18* alone. In detail, for the MCF-7 cells, the internalization of N50-sC18* was about 5-times 
higher, whereas for NrTP-sC18* the uptake was even about 20-times higher than the ones of 
the cell-penetrating sequence alone. NrTP-sC18* seemed to internalize better into the breast 
cancer cells than N50-sC18*. In HeLa cells, the measured values were actually above the ones 
in MCF-7 cells, indicating a better penetration within the cervix cancer cells. Furthermore, the 
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values for the chimeric peptides were about 30-times higher than for sC18*. Hereby, it is 
obvious that the internalization rates for N50-sC18* and NrTP-sC18* were different from the 
ones in MCF-7 cells.  
Anyway, the evident increase of internalized peptides confirmed the hypothesis, that due to 
the potent formation of α-helices, the chimeric sequences N50-sC18* and NrTP-sC18* were 
able to interact with the cell membranes in an even better way than sC18* alone, and the 
peptides could then translocate into the cells in highly efficient rates.  
 
4.3.3 Defining the intracellular localization cells after internalization  
Despite the fact that the newly described CPPs N50-sC18* and NrTP-sC18* translocated into 
the two observed cancer cells in high rates, it is not known how they behave afterwards and 
especially where they are located within the cells. As they carry a sequence that should trigger 
the transport to the nuclei or nucleoli, they presumable localize within the cell nuclei. To verify 
this idea, microscopic analyses were performed after incubating the cells with 10 µM of the 
CPPs. The results for HeLa cells are presented in figure 26.  
 
 
Figure 26: Uptake and distribution of CPP variants in HeLa cells. Fluorescence microscopy images 
after 30 min incubation with 10 µM CF-labeled peptides sC18*, N50, N50-sC18*, NrTP and NrTP-sC18* 
at 37 °C, respectively. For the right merge pictures, cells were incubated with 10 µM of the peptides N50 
and NrTP for 30 or 120 min, Blue: Hoechst nuclear stain, Green: CF-labeled peptides, external 
fluorescence was quenched with trypan blue for 30 s, Scale bar is 10 µm. 
 
It could be shown that sC18*, as expected from the flow cytometry results, was only marginally 
taken up compared to N50-sC18* and NrTP-sC18*. Only small dots were detectable, which 
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were probably representing vesicles, since an endocytotic uptake way for this CPP and its 
longer version sC18 were already demonstrated (chapter 4.1) [19, 73, 77]. Observing the 
microscopic pictures on the right side of the figure, the nuclear localization sequence N50 
alone was not noticeable present within the cells at this concentration, not even after a longer 
incubation period of two hours. In contrast, the uptake rate of the fusion peptide N50-sC18* 
was much higher compared to the two peptides sC18* and N50 alone, which was also 
confirmed by the flow cytometry results (figure 25). Examining the localization of the CPP, it is 
obvious that the CF-labeled peptide was distributed in the whole cell. It seemed to accumulate 
within the cytoplasm, especially around the nucleus, but also a diffuse green signal could be 
registered, indicating free peptide, which was not enclosed in vesicles. In addition to that, the 
peptide was capable to overcome the cell nuclei membrane and also accumulated in the nuclei. 
The same localization pattern and amount of internalized peptides could be observed after 
2 hours of incubation (data not shown).  
More or less the same results could be examined for the peptides NrTP and NrTP-sC18*. The 
NrTP sequence alone was not detectable after incubation of HeLa cells for 30 min, but after a 
longer incubation period of two hours, some green signals within the cytoplasm could be 
observed. Notably, for the fusion peptide NrTP-sC18* a much higher internalization rate could 
be detected and especially for this CPP a strong accumulation within the nucleoli was visible. 
This confirmed the theory that the NrTP sequence is targeting these regions in the nuclei [35]. 
Also for this fusion peptide, studies after 120 minutes were done and the uptake was even 
slightly higher after this period of incubation (data not shown). As the internalization with 10 µM 
of the peptides was already really high and the accumulation, especially for N50-sC18* was 
not precisely detectable caused by an intense green signal in the whole cell, another set of 
microscopic observations was performed using a lower peptide concentration of 1 µM. The 
results for the fusion peptides are presented in figure 27.  
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Figure 27: Uptake and distribution of CPP variants in HeLa cells at low concentrations. 
Fluorescence microscopy images after 30 or 120 min incubation with 1 µM CF-labeled peptides 
N50-sC18* or NrTP-sC18* at 37 °C, respectively. Blue: Hoechst nuclear stain, Green: CF-labeled 
peptides, external fluorescence was quenched with trypan blue for 30 s, Scale bar is 10 µm. 
 
Next to this, also the shorter fractions, namely sC18*, N50 and NrTP alone were tested at 
these concentrations for 30 and 120 min, but hereby no green signal could be registered (data 
not shown). On the contrary, the pictures in figure 27 show that both fusion peptides were able 
to internalize the cells in efficient ways. Obviously, the uptake was less compared to the rates 
at a concentration of 10 µM.  
For the upper pictures representing the peptide N50-sC18*, also an adequate signal within the 
nuclei could be identified. Next to this, a diffuse signal within the cytoplasm was visible, 
supporting the idea, that the peptides entered the cells by direct penetration or by endocytosis 
with a subsequent release from the vesicles. Then, they are able to overcome the nuclear 
membrane [27]. After exposing the peptides for 2 h to the HeLa cells, the diffuse signal in the 
cytoplasm seemed to decrease and a more precise accumulation within the nuclei was 
detectable. 
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In contrast to this, the uptake of 1 µM of NrTP fused to sC18* indicated that the CPP at this 
concentration was able to enter the cells, but then seemed to accumulate in endosomes or 
somewhere else within the cytoplasm. The peptide was neither detectable in the nuclei nor in 
the nucleoli. The distribution was punctual so it is possible that the peptides entered into the 
cells at this concentration via endocytosis, but the concentration of the CPP was probably not 
high enough to escape from the vesicles. Hence, it was not possible for the peptides to interact 
with the nuclei membranes. This observation was different from the one that was made in 
figure 26, but it is known that the internalization ways of CPPs are depending among many 
factors besides their concentration [10]. So, one can conclude, that for NrTP-sC18*, the 
concentration should be higher than 1 µM for an efficient intracellular targeting to the organelle. 
Also a longer incubation time, as shown for 120 min, is not triggering the endosomal release, 
even when the intensity of green signal within the cells was slightly higher than after 30 min of 
incubation. 
Consequently, it can be said that the fusion of N50 and NrTP to sC18* led to higher 
internalization rates and localization in the nuclei and nucleoli at a certain concentration, 
respectively. Taking all observations in consideration, the cell-penetrating peptide sC18* was 
probably bringing the CPPs within the cells and the combination of the amino acids of N50 and 
NrTP was triggering the transport to the cell nuclei and nucleoli. Anyway, showing much higher 
uptake rates of the fusion peptides, one can suggest that the combination of the two peptides 
also increased the ability to interact with the plasma membrane, probably due to the higher 
amount of positive charges, which could end in longer and stabilized α-helices.  
Next, MCF-7 cells were investigated regarding the uptake of the new CPP variants. The 
microscopic analyses are depicted in the figures 28 and 29.   
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Figure 28: Uptake and distribution of CPP variants in MCF-7 cells. Fluorescence microscopy 
images cells after 30 min incubation with 10 µM CF-labeled peptides sC18*, N50, N50-sC18*, NrTP and 
NrTP-sC18* at 37 °C, respectively. For the right merge pictures, cells were incubated with 10 µM of the 
peptides N50 and NrTP for 30 or 120 min, Blue: Hoechst nuclear stain, Green: CF-labeled peptides, 
external fluorescence was quenched with trypan blue for 30 s, Scale bar is 10 µm. 
 
Evaluating figure 28 on the left side, the peptide sC18* internalized into MCF-7 cells probably 
via endocytosis. Moreover, the uptake seemed to be higher compared to HeLa cells. Again, 
no green fluorescence could be detected within the cell nuclei. Next to this, no visible uptake 
of the N50 sequence alone could be noticed, not even after an incubation time of 120 min. In 
contrast to this, the fusion peptide N50-sC18* was taken up by the cancer cells in high 
amounts, and furthermore, the peptides were able to localize within in the cell nuclei. Within 
the cytoplasm, a diffuse distribution as well as various agglomerations of green signal could 
be observed. So, the fusion of N50 to sC18* leads to higher internalization rates and a 
successful localization in the nuclei. The intensity of the green signal of labeled N50-sC18* is 
slightly reduced after an incubation time of 120 min (data not shown). This could be explained 
by a certain more precise dispersion towards the target and a degradation of unbound peptide 
in the cytoplasm. For a deeper understanding of the remaining CPPs after a longer exposition, 
more experiments should be performed. 
Regarding the internalization of NrTP and NrTP-sC18*, a slightly different outcome compared 
to HeLa cells could be seen. Evaluating the microscopic pictures depicted in figure 28, the 
peptide NrTP was also capable to internalize in the cells by itself in small amounts and 
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localized mainly in the nucleoli as it is thought for. This effect could not be observed after 
120 min (figure 28 right side). Anyway, as described above, the fusion of the two peptide 
sequences led to higher uptake rates and a strong co-localization with the cell nuclei and, 
especially visible in MCF-7 cells, with the nucleoli. Hereby, again the uptake after 120 min 
seemed to be less diffuse than after 30 min (data not shown). For a superior explanation of 
this phenomenon, more investigations need to be done. Also here, MCF-7 were treated with a 
concentration of 1 µM of the fusion peptides for 30 and 120 min, the results are presented in 
figure 29. 
 
 
Figure 29: Uptake and distribution of CPP variants in MCF-7 cells at low concentrations. 
Fluorescence microscopy images after 30 or 120 min incubation with 1 µM CF-labeled peptides 
N50-sC18* or NrTP-sC18* at 37 °C, respectively. Blue: Hoechst nuclear stain, Green: CF-labeled 
peptides, external fluorescence was quenched with trypan blue for 30 s, Scale bar is 10 µm. 
 
Hereby, the results were different from the ones with HeLa cells shown in figure 27. The only 
visible signal, which could be detected at this concentration, was after the treatment with NrTP-
sC18* for 30 min. No uptake for sC18*, N50 and NrTP alone (data not shown), N50-sC18* 
(30 and 120 min) and NrTP-sC18* after 120 min could be seen. Comparing these results with 
the ones of the flow cytometer shown in figure 25, it could be proven that the uptake of 
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NrTP-sC18* is higher than the uptake of N50-sC18* also at low concentrations. The fact, that 
the CPP NrTP-sC18* was not visible after 120 min is also in correlation to the previously 
presented microscopic results (figure 28). Anyway, a prominent localization within the cell 
nucleoli in the MCF-7 cells could be noted.   
 
4.3.4 Microscopic analysis of uptake at 4 °C 
From previous studies, it was presumed that the CPPs enter the cells by direct penetration or 
by endocytosis followed by an endosomal release, which could already be shown for the CPP 
(sC18)2 (chapter 4.2). Otherwise, they would not be untrapped in the cytosol and could not 
penetrate the cell nuclei membranes [27]. Another uptake study performed at 4 °C was done 
to get detailed insights into the mechanism of internalization. Hereby, the energy dependent 
pathways were shut down and the CPPs could just enter the cells by direct penetration [91]. 
MCF-7 and HeLa cells were treated with the fusion sequences for 30 min at 4 °C and were 
observed using a confocal laser scanning microscope. The pictures are presented in figure 30 
for HeLa cells, and the results for MCF-7 cells are shown in figure 31.  
 
 
Figure 30: Uptake of CPP variants in HeLa cells at 4 °C. Fluorescence microscopy images after 
30 min incubation with 10 µM CF-labeled peptides N50-sC18* or NrTP-sC18* at 4 °C, respectively. 
Blue: Hoechst nuclear stain, Green: CF-labeled peptides, external fluorescence was quenched with 
trypan blue for 30 s, Scale bar is 10 µm. 
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Figure 31: Uptake of CPP variants in MCF-7 cells at 4 °C. Fluorescence microscopy images after 
30 min incubation with 10 µM CF-labeled peptides N50-sC18* or NrTP-sC18* at 4 °C, respectively. 
Blue: Hoechst nuclear stain, Green: CF-labeled peptides, external fluorescence was quenched with 
trypan blue for 30 s, Scale bar is 10 µm. 
 
As shown in the previous figures, a prominent green signal for both cell-penetrating peptides 
N50-sC18* and NrTP-sC18* in HeLa and MCF-7 cells could be registered, which was visible 
in a diffuse signal distributed in the cytoplasm and strong accumulations in the cell nuclei and 
nucleoli. This leads to the interpretation that the sequences internalized into the cells in high 
amounts by direct penetration, because an internalization by endocytosis is suppressed at 
4 °C [91]. These results are in coincidence with the uptake at 37 °C, whereby the peptides are 
capable to overcome the nuclei membranes. Therefore, the CPPs need to be free in the 
cytoplasm and an encapsulation within vesicles would hinder them in this step.  
This uptake by direct penetration could already be published for many well studied cell-
penetrating peptides, for example for the arginine-rich peptide TAT(48-60), which was used in 
numerous applications as delivery vectors [16, 116].  
 
4.3.5 Defining the intracellular localization of CPPs 
Until now, it is not clear, if the green signals that were distributed in the cytoplasm were just 
randomly spread peptides or if the CPPs accumulate in specific organelles. To get a better 
understanding about this, additional ER- and lysosomal tracker were used to stain the 
organelles in red. If the CF-labeled peptides accumulated in these compartments, the overlay 
of the green and red signals would appear yellow.  
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The studies with the endoplasmic reticulum marker in MCF-7 and HeLa cells did not show any 
co-localization of N50-sC18* or NrTP-sC18* with the ER. Therefore, an accumulation within 
the ER could not be determined. (data not shown) 
Using the lysotracker in MCF-7 cells, no satisfying staining could be obtained (data not shown). 
The obtained results in HeLa cells appeared better and are shown in figure 32. 
 
 
Figure 32: Intracellular localization of NrTP-sC18* and N50-sC18* in HeLa cells. Fluorescence 
microscopy images after 30 min incubation with 10 µM CF-labeled peptides N50-sC18* or NrTP-sC18* 
and 75 nM of lysosomal marker, respectively. Blue: Hoechst nuclear stain, Green: CF-labeled peptides, 
Red: Lysotracker, external fluorescence was quenched with trypan blue for 30 s, Scale bar is 10 µm. 
 
As depicted in figure 32, the lysosomal staining in HeLa cells was successful. In merge 
pictures, one could notice some yellow regions indicating a localization of the CPPs in the 
lysosomes. Anyway, there were also many regions, where the peptides accumulated in other 
regions within the cytoplasm. It is possible that this accumulation did not occur in specific 
organelles in the cells, but just in agglomerations of the peptides in higher amounts. Some 
parts of the nuclei showed red fluorescence, indicating that the staining was not lysosome 
specific and should be improved further.  
 
4.3.6 Cytotoxic profile of nuclei-targeting CPPs 
After detailed investigation of the internalization and localization of the peptides, a closer look 
at their cytotoxicity profiles was taken. Therefore, MCF-7 and HeLa cells were exposed for 
24 h to the CPPs sC18*, N50, N50-sC18*, NrTP and NrTP-sC18* in various concentrations 
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and then, the number of viable cells was determined. The results of the experiments are shown 
in figure 33.  
 
 
Figure 33: Cytotoxic profile of CPP variants for MCF-7 and HeLa cells. Cell viability assay based 
on resazurin after incubation with the CPPs sC18*, N50, N50-sC18*, NrTP and NrTP-sC18* for 24 h in 
various concentrations, untreated cells served as negative control and were set to 100%. 70% EtOH 
was used as positive control, which was subtracted from all results. Experiments were conducted in 
triplicate with n = 2. Error bars represent the standard deviations. 
 
It is observable that none of the peptides was toxic to MCF-7 cells up to a concentration of 
100 µM. Also after treating HeLa cells with the peptides, no significant toxicity for the CPPs 
sC18*, N50, N50-sC18* and NrTP up to a concentration of 50 µM could be observed. At 
100 µM, the incubation with sC18*, N50-sC18* and NrTP resulted in a decrease of viable cells 
to about 80%. Horn et al. showed that sC18* is not toxic to MCF-7 and HEK-293 cells up to a 
concentration of 200 µM. To HeLa and HCT-15 cells, the CPP demonstrated slight cytotoxic 
effects at a concentration of 200 µM. [73] This is in correlation with the results obtained in this 
work. In contrast, for the chimeric peptide sequence NrTP-sC18* in HeLa cells at a 
concentration of 50 µM, about 50% of the cells were still viable whereas at a concentration of 
100 µM all cells were dead. This observation is in agreement with the previously presented 
results of flow cytometric analyses, whereby it could be shown that the internalization rates of 
the chimeric variants are much higher in HeLa cells than in MCF-7 cells. Therefore, it is likely, 
that the interaction with the cervix cancer cell membranes was stronger and led to a disruption 
of the membrane, which caused cell death in the end. This idea could be confirmed by the 
execution of a cell lysis assay described above. However, all uptake experiments that were 
done with the peptides were conducted at concentrations between 1 and 10 µM, whereby they 
did not show toxic effects on the cells.  
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4.3.7 Complexation capability with pEGFP-N1 and pGL4.13 
As described in the introduction, in many approaches, it is necessary to deliver DNA into cells 
and certainly into the nucleus. An electromobility shift assay (EMSA) with N50-sC18* and 
NrTP-sC18* was performed to register if the peptides are able to form complexes with plasmid 
DNA, which is necessary for its transport into the cells. Both sequences carry a high number 
of positive charges (12 for N50-sC18* and 13 for NrTP-sC18*), which theoretically enable them 
to interact with negatively charged plasmid DNA [117]. These differently charged components 
should form electrostatic complexes for efficient transport of the DNA to the cells. The ratios 
were calculated according to the negative charge of the DNA and the positive charges of the 
CPPs. For the EMSAs, a plasmid concentration of 100 ng was taken for good visibility on the 
agarose gel. If a complexation takes place, the electrophoretic migration rate of the DNA is 
reduced in comparison to naked DNA and therefore, the plasmid remains in the loading pocket 
of the gel. In figure 34, the assay is shown for the vector pEGFP-N1, the concentrations of 
N50-sC18* were 0.62 µM (1:1), 3.09 µM (5:1), 6.18 µM (10:1) and 18.56 µM (30:1), 
respectively. NrTP-sC18* was used in the following concentrations: 0.57 µM (1:1), 2.86 µM 
(5:1), 5.71 µM (10:1) and 17.14 µM (30:1). 
 
 
Figure 34: Complexation studies of CPPs with pEGFP-N1. Electromobility shift assay (EMSA) using 
the CPPs N50-sC18* (A) or NrTP-sC18* (B) and the plasmid pEGFP-N1 after complexation for 30 min 
in different charge ratios (1:1, 5:1, 10:1, 30:1), pEGFP-N1 plasmid alone served as negative control.    
 
Evaluating the EMSAs in figure 34, one can notice that both peptides, namely N50-sC18* and 
NrTP-sC18*, were able to form complexes with the plasmid pEGFP-N1 in the ratios 5:1, 10:1 
and 30:1. At a ratio of 1:1, the DNA could still move to the positively charged anode like the 
control plasmid, whereas the bigger complexes were not able to move through the agarose 
matrix. For the complexation at 5:1 ratio, still some traces of free DNA were visible. Hence, for 
the transfection using the EGFP-plasmid, a charge ratio of 10:1 was used.  
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Additionally, another plasmid was used in this study and therefore another EMSA was 
performed using the luciferase encoding vector pGL4.13 [luc2/SV40] (figure 35). The ratios 
were also calculated from the charges of CPPs and plasmid and a vector concentration of 
100 ng was chosen. The concentrations of N50-sC18* were 0.63 µM (1:1), 3.16 µM (5:1), 
6.31 µM (10:1) and 18.94 µM (30:1) and of NrTP-sC18* 0.58 µM (1:1), 2.91 µM (5:1), 5.83 µM 
(10:1) and 17.48 µM (30:1). 
 
 
Figure 35: Complexation studies of CPPs with pGL4.13. Electromobility shift assay (EMSA) using 
the CPPs N50-sC18* (A) or NrTP-sC18* (B) and the plasmid pGL4.13 [luc2/SV40] after complexation 
for 30 min in different charge ratios (1:1, 5:1, 10:1, 30:1), pGL4.13 plasmid alone served as negative 
control.    
 
In figure 35, it is visible that the complexation of the CPPs with the plasmid pGL4.13 occurred 
at a concentration of 30:1. At lower ratios, only partly complexation was visible. Consequently, 
the ratio of 30:1 was used in further experiments.  
 
4.3.8 Transfection of MCF-7 and HeLa cells  
Next, it was investigated, if the fusion peptides are able to deliver pDNA into cells. For 
transfection with the GFP encoding plasmid pEGFP-N1, cells were seeded in 8-well ibidis and 
treated with the peptide/vector complexes for 6 hours. After 48 hours, meanwhile the cells 
could express the green fluorescent protein, they were observed under the microscope. The 
pictures are presented in figure 36. 
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Figure 36: Transfection studies of CPPs with pEGFP-N1. Transfection of MCF-7 and HeLa cells with 
the plasmid pEGFP-N1 after complexation for 30 min with the peptides N50-sC18* or NrTP-sC18* with 
or without 100 µM chloroquine at a ratio of 10:1. 300 ng of plasmid were used, plasmid alone served as 
negative control, for positive control Lipofectamine®2000 was complexed with the vector for 5 min, 
Merge pictures are shown, Scale bar is 10 µm. 
 
It is visible that in the negative control, whereby just plasmid alone was given to the cells, no 
green signal could be detected. On the contrary, after treating the MCF-7 and HeLa cells with 
the transfection reagent Lipofectamine®2000 and the vector, some green cells, which 
expressed the green fluorescent protein, could be detected. This confirms a successful positive 
control of the experimental setup. However, for both cell lines, not any transfected cell after 
treatment with the CPP/plasmid complexes was observed. Furthermore, also the addition of 
the endosomal release triggering agent chloroquine did not lead to successful transfection. 
Notably, if the peptides internalize into the cells by direct penetration, as it is assumed from 
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the former studies, the chloroquine would be redundant and should not have any effect on the 
cells. Hence, other ways for the improvement of transfection efficiency should be tried in the 
future. 
The transfection experiments were furthermore performed using the other plasmid DNA, 
namely the pGL4.13 vector that encodes for the firefly luciferase enzyme. Cells were seeded 
in 96-well plates and treated with the complexes for 6 hours. As for the previously described 
assay, the cells were afterwards incubated for 48 hours and thereafter, a luciferase assay 
reagent containing beetle luciferin, which can be oxidized by luciferase to oxiluciferin, was 
added to each well. During this reaction, a flash of light is generated that can be detected with 
a plate reader measuring the luminescence [118]. To improve the transfection rate, 
chloroquine was added as well. The results of these experiments can be seen in figure 37.  
 
 
Figure 37: Transfection studies of CPPs with pGL4.13. Transfection of MCF-7 and HeLa cells with 
the plasmid pGL4.13 [luc2/SV40] after complexation for 30 min with the peptides N50-sC18* or 
NrTP-sC18* with or without 100 µM chloroquine at a ratio of 30:1. 300 ng of plasmid were used, plasmid 
alone served as negative control, for positive control Lipofectamine was complexed with the vector for 
5 min. Experiments were conducted in triplicate with n = 2 (except for the CQ experiments with n = 1), 
error bars represent the standard derivation. 
 
First, it can be concluded that in both cell lines, the positive control using the transfection 
reagent Lipofectamine was able to successfully transfect the cells. The results are evidently 
better in HeLa than in MCF-7 cells, which was similar to the results for the transfections with 
the pEGFP-N1 vector (figure 36). Apart from that, one can say that the transfection with the 
tested CPPs was not successful. Looking at the HeLa cells, no transfection at all could be 
noticed. In MCF-7 cells, a slight signal of the cells transfected with the peptide NrTP-sC18* 
could be executed, but this result was not statistically significant. Taking the uptake studies of 
the two combined CPPs in MCF-7 cells in consideration, whereby the NrTP-sC18* show 
apparent higher internalization than N50-sC18* (figure 25), one can conclude that this was 
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correlated to the transfection efficiency. NrTP-sC18* is taken up in higher amounts and can 
therefore probably bring more plasmid DNA into the cancer cells, which results in low 
expression of the luciferase-encoding vector.  
The results of the experiments using the endosomal release triggering agent chloroquine, that 
were incidentally just done once, need to be considered cautiously. Hereby, the chloroquine 
was added directly to the solution when mixing the reagents for the complexation. Maybe, a 
higher output can be observed, adding the CQ later, when giving the complexes to the cells, 
as Rennert et al. did in their studies in 2008 [119]. Furthermore, there are other possibilities to 
enhance the transfection potential of cell-penetrating peptides. Cationic polymers like 
polyethyleneimines (PEI) could be added in low concentrations, so that the acidification 
process which is essential for the transition from endosomes to lysosomes is slowed down 
[120]. Another possibility to improve the transfection rate is the addition of inactivated viral 
particles or recombinant proteins. They have the capability to disrupt endosomes or free 
radicals and could therefore cause membrane damage [121, 122]. A further alternative is the 
introduction of a fatty acid. Futaki et al. showed in 2001 that in this way the transfection 
efficiency of octaarginine could be enhanced. [123] Also the delivery of siRNA could be 
improved by fatty acid-CPPs conjugates [110]. 
Another aspect that needs to be considered is the fact that the peptides seem to enter the cells 
by direct penetration. Their ability to form complexes with the negatively charged plasmid DNA 
does not say anything about the entering pathway of the peptide/DNA complexes. As it is 
known that CPPs can internalize cells in various pathways and direct penetration and 
endocytosis can also occur simultaneously, it is possible that some peptide/plasmid complexes 
can enter the cells via endocytosis [26]. Maybe, the DNA is transported by the CPPs within the 
cells, but then the interaction capability is disturbed by intracellular proteins or peptides and 
the DNA is degraded by cellular DNases before entering the cell nuclei [124]. Anyway, due to 
the fact that the effective gene delivery is subordinated to the endosomal uptake pathway and 
the transfection efficiency was low in both experiments, the results confirmed an uptake by 
direct penetration for the CPPs N50-sC18* and NrTP-sC18*. [125, 126] 
 
4.3.9 Cargo delivery of Doxorubicin  
Since the pDNA delivery studies were not successful in the first try, the transport capability of 
N50-sC18* and NrTP-sC18* were investigated in further experiments with smaller cargoes. 
Therefore, HeLa and MCF-7 cells were exposed to the chemotherapeutic drug doxorubicin 
(DOX) that is already used to treat cancer [http://www.cytrx.com/aldoxorubicin, 24.09.2017]. 
Doxorubicin interacts with DNA by intercalation and thereby inhibits the macromolecular 
biosynthesis [127, 128]. Some publications reported that the covalent binding of doxorubicin 
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to different CPPs induced cell death in various cell lines [129, 130]. Furthermore, doxorubicin 
is known to be fluorescent [131] and this property was used in a first approach to test, if the 
peptides were able to trigger the transport of the drug into the cells. Therefore, DOX and the 
sequences N50-sC18* and NrTP-sC18* were co-incubated with HeLa and MCF-7 cells, 
respectively and observed for red fluorescence afterwards. The results are shown in figures 
38 and 39.  
 
 
Figure 38: Uptake and delivery of DOX into HeLa cells. Fluorescence microscopy images after 
30 min incubation with 10 µM CF-labeled peptides N50-sC18* or NrTP-sC18* co-incubated with 
10 µg/ml doxorubicin at 37 °C, respectively. Cells treated with DOX alone served as negative control, 
Blue: Hoechst nuclear stain, Green: CF-labeled peptides, Red: doxorubicin, external fluorescence was 
quenched with trypan blue for 30 s, Scale bar is 10 µm. 
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Figure 39: Uptake and delivery of DOX into MCF-7 cells. Fluorescence microscopy images after 
30 min incubation with 10 µM CF-labeled peptides N50-sC18* or NrTP-sC18* co-incubated with 
10 µg/ml doxorubicin at 37 °C, respectively. Cells treated with DOX alone served as negative control, 
Blue: Hoechst nuclear stain, Green: CF-labeled peptides, Red: doxorubicin, external fluorescence was 
quenched with trypan blue for 30 s, Scale bar is 10 µm. 
 
As depicted in the figures 38 and 39 the cell nuclei appeared in normal shape confirming the 
applied concentrations not to be toxic when given for 30 min to the cells. Furthermore, a slight 
red fluorescence could be detected in the negative control, indicating that the 
chemotherapeutic drug was also able to translocate in the cells by itself at this concentration. 
Apart from that, looking at the bottom pictures showing the co-incubation of DOX with the 
CPPs, one can say that the intensities of the red fluorescent signals visible in the cell nuclei 
were more intense compared to the negative control. This effect was more intense in MCF-7 
cells. As a result, these pictures could give a first hint about the drug transport capability of the 
peptides N50-sC18* and NrTP-sC18* in the two observed cancer cells lines. As this is just a 
first estimation, in the following, a killing assay was established to verify the transport and toxic 
effects of the drug.  
Therefore, doxorubicin was incubated for 48 hours at different concentrations. It turned out that 
5, 10 and 15 µg/ml doxorubicin was to high for these experiments, because no viable cells 
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could be detected after the treatment (data not shown). At 0.1 and 0.5 µg/ml all cells remain 
viable after the experiment (data not shown), so these concentrations were too low. At a 
concentration of 1 µg/ml in MCF-7 cells, the cell viability decreased to about 60%. At this 
concentration doxorubicin seemed to be high enough to theoretically kill the cells, thus the 
following assay was done under these conditions. Hence, 48 h after the treatment with the 
drug alone or co-incubated with 10 µM of the peptides sC18*, N50-sC18* and NrTP-sC18*, a 
cell viability assay was performed, whose results are shown in figure 40. 
 
 
Figure 40: Cargo delivery of doxorubicin in HeLa and MCF-7 cells. Cytotoxicity assay based on 
resazurin after incubation with 1 µg/ml doxorubicin, 10 µM sC18*, N50-sC18* or NrTP-sC18* alone or 
co-incubated with 1 µg/ml doxorubicin for 48 h, respectively. Untreated cells served as negative control, 
cells treated for 10 min with 70% EtOH as positive control. Experiments were conducted in triplicate with 
n = 2, error bars represent the standard derivation. 
 
As it is depicted in figure 40, the cargo delivery ability of the CPPs was different according to 
both cancer cell lines. In HeLa cells, the doxorubicin alone and also the CPPs alone did not 
show any toxicity. Furthermore, the co-incubation of the agent with the chimeric peptides 
N50-sC18* and NrTP-sC18* also did not lead to a decreased cell viability. The results for the 
positive control were successful with a remaining number of viable cells of about 5%, so the 
assay was per se working properly. For the doxorubicin control, it seemed that the applied 
concentration of 1 µg/ml is not high enough to harm the cells. The tests on HeLa cells should 
be repeated using another, higher doxorubicin concentration.  
In contrast to that, the experiments on MCF-7 cells were more successful. As shown in figure 
40 on the left hand side, the treatment with doxorubicin alone ended up in a number of viable 
cells about 60%. The peptides alone were not toxic at a concentration of 10 µM, which was 
already mentioned in chapter 4.3.6. In contrast, when co-incubating the CPPs and the 
chemotherapy drug, the toxic effect of doxorubicin could be improved. After treatment with 
N50-sC18*, the number of viable cells was around 30%, for NrTP-sC18* around 40%. The 
effect of doxorubicin could be enhanced about 20 – 30% when triggering its transport to the 
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cell nuclei in MCF-7 cells. To show that this effect was not caused by the sC18* sequence, this 
CPP was tested in co-incubation in the same conditions. Hereby, no difference to the treatment 
with doxorubicin alone could be observed. This proved that the combination of the nuclear 
targeting sequences N50 and NrTP and the cell-penetrating peptide sC18* led to an increased 
transport of the drug to the cells and their nuclei. Then, the chemotherapeutic drug could fulfil 
its function, intercalated with the DNA and finally led to cell death in a high number of cells. 
These results show that the CPPs N50-sC18* and NrTP-sC18* support the transport of the 
chemotherapeutic drug doxorubicin into breast cancer cells. Interestingly, the herein presented 
non-covalent approach is very efficient, compared to a recent described CPP-mediated DOX 
transport, where the drug was covalently coupled to the CPP [130]. 
Summarizing the fusion of the nuclear localization sequences N50 and NrTP to the CPP sC18* 
resulted in two peptides, that showed extremely high uptake rates and specific localization in 
the cell nucleus.  
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5 CONCLUSION AND OUTLOOK 
 
5.1 Summary and conclusion of studies with linear and 
branched dimeric sC18 versions 
This chapter examined the investigation of the two cell-penetrating peptides sC18 and sC18*, 
as well as their dimeric, precisely branched and linear, versions.  
All peptide variants were successfully synthesized via solid-phase peptide synthesis in an 
unlabeled and CF-labeled version. The results of circular dichroism spectroscopy revealed that 
all peptide variants were able to exhibit an α-helical structure in the presence of TFE. Moreover, 
all variants internalized in higher extent into cancer cells than in non-cancer cells, pointing to 
a potential cell selectivity. Furthermore, the internalization rate of the dimeric peptides (sC18)2, 
(sC18*)2, lin(sC18)2 and lin(sC18*)2 was increased compared to their monomeric forms, 
however no significant difference between the dimerized versions could be obtained. The 
cytotoxic profiles revealed that the short peptide versions did not exhibit cytotoxic effects to 
both cell lines in the tested concentrations and furthermore, no cell lysis could be detected. In 
contrast to this, all dimeric CPPs exhibited a more toxic effect on MCF-7 cells than on HEK-293 
cells and showed also high membrane lysis events in the cancer cell line. The two branched 
variants in HEK-293 cells did not show a difference in toxicity, whereas in MCF-7 cells the 
truncated version (sC18*)2 was less toxic and fewer membrane lysis compared to the longer 
version (sC18)2 could be demonstrated. Also the linear variants showed the same toxicity as 
the branched ones in HEK-293 cells, but in MCF-7 the linear sequences were slightly more 
toxic. One can conclude that the branching of the peptide sequence led to a reduction of the 
cytotoxicity.  
The selectivity of the peptides for the different cell types could be explained by investigating 
different artificial membrane systems, whereby it could be demonstrated that the CPPs were 
not able to overcome neutrally charged membranes, which represent the plasma membranes 
of non-cancer cells. In contrast to this, the accumulation of the peptides on negatively charged 
vesicles, symbolizing cancer cell membranes, was very high. This might be an explanation for 
the increased internalization and cytotoxicity of the CPPs into the cancer cell line MCF-7. 
The microscopic analysis illustrated that the different toxicity profiles were not correlated to the 
amount of CPP within the cell, since all longer peptide versions exhibited an equal uptake rate. 
This leads to the conclusion, that a membrane disrupting process during internalization of the 
peptides was responsible for the different cytotoxicities. The LDH release assay revealed an 
efficient membrane disrupting event at a concentration of 10 µM for 1 h of the longer peptides 
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versions. Since the microscopic analyses were performed using 10 µM for 30 min, it is likely 
that the high uptake rates are correlated with the membrane destabilization induced by the 
CPPs. As the cell nuclei appeared normally and healthy, an evocation of toxicity did not happen 
after this short period of time. The toxicity assays were performed after 24 hours of incubation 
with the peptides. So, it is likely that the membrane disruption of the CPPs led to higher 
penetration rates with a followed cell death induced some hours later. 
Stephanie Natividad-Tietz investigated in previous experiments the transfection capacity of all 
variants in HEK-293 cells. Thereby, it was shown that the branched and linear peptides 
revealed slightly higher transfection rates than the monomeric peptides sC18 and sC18*. 
Anyway, there were no significant differences among each other and the transfection rate for 
all tested sC18 derivatives were extremely poor compared to the commonly used transfection 
reagent Lipofectamine®2000. [Natividad-Tietz, Dissertation 2016] 
Taking all results of this study in consideration, it can be concluded, that the longer dimeric 
branched variant (sC18)2 showed the highest potential for a lytic anticancer peptide. Without 
the branching, the sequence forms a longer helix, compared to the branched versions, which 
exhibited two α-helical structures linked by a peptide bond. Maybe this was triggering the more 
intense membrane disruption by lin(sC18)2. Thus, the branching decreased the unselective 
toxic property, resulting in a higher selectivity against cancer cells.  
 
5.2 Summary and conclusion of (sC18)2 studies 
In chapter 4.2, a more detailed investigation of the dimeric cell-penetrating peptide (sC18)2 in 
comparison to its monomeric parent peptide sC18 was performed. In flow cytometric analysis, 
the different uptake rates of the CPPs could be affirmed. The translocation rates of (sC18)2 
were much higher than the ones of the monomer sC18 in both cell lines. Moreover, the 
internalization into the cancer cell line MCF-7 was much higher than into the non-cancer cells 
HEK-293. Nevertheless, at very low concentrations of 0.823 nmol, which could be elucidated 
with the radiolabeled NODAGA-coupled peptides, no difference in the internalization rates of 
both peptides in both cell lines occurred. This demonstrated, that the peptide selectivity was 
only given at concentrations in the micromolar range.  
Besides, it could be demonstrated that the internalization rates were decreased at 4 °C, 
whereby all energy-dependent mechanisms were highly reduced in the cells. This effect was 
very distinct in HEK-293 cells, leading to the hypothesis that sC18 and (sC18)2 penetrate the 
cells mainly by endocytosis. This theory was confirmed by observing the cells six hours after 
incubation with the peptides, where still all green signals were present in vesicles. The CPPs 
seemed to be entrapped in endosomes and be then degraded in the lysosomal pathway, which 
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is also explaining why they never occurred in the nuclei of the non-cancer cells. Anyway, 
various reagents like chloroquine, calcium and sucrose could trigger the endosomal release in 
this cell line. The experiment with endosomal release triggering substances was more efficient 
for the dimer than for the monomer, but was not caused by toxic or lytic effects.  
In the cancer cells, the CPPs also occurred within the nuclei, indicating an endosomal release, 
so that they were able to overcome the nuclei membrane. The internalization was not fully 
inhibited at 4 °C, indicating a combination of endocytosis and direct penetration, which could 
still occur at low temperatures. Furthermore, six hours after incubation with the CPPs, almost 
no green signal could be detected in the cells. It is likely, that the peptides were able to leave 
the endosomes, could translocate in the nuclei and were degraded within the cytoplasm after 
distinct amount of time. 
An internalization and cytotoxicity screening of sC18 and (sC18)2 on several different cell lines 
confirmed that the uptake in cancer cell lines was increased compared to the non-cancer cells 
HEK-293. Furthermore, also the toxicity studies approved a specific preference for the 
neoplastic plasma membranes. The IC50 values were in the lower micromolar range in all 
different types of cancer cells that were investigated.   
The cancer cell selectivity of (sC18)2 was a consequence of the peptide-lipid interactions 
depending on the lipid charge, which was verified on various artificial membrane systems. It 
was demonstrated that the interaction of both peptides with neutrally charged membranes 
were minimal and no disruption could be observed. In contrast, looking at the experiments with 
the negatively charged membranes, that were more resembling cancer cell membranes, the 
accumulation of the CPPs was very outstanding. Furthermore, (sC18)2 was even able to 
disrupt the vesicles, which led to a release of the enclosed dyes. It could also be shown that 
cholesterol played an important role for the interaction with the membranes, even when the 
disrupting effect was diminished compared to the negatively charged vesicles.  
Additionally, an efficient transport capability of the active drug actinomycin D could be 
presented, which resulted in the effective reduction of viable cells in comparison to the cells 
incubated with the drug or peptide alone, respectively. In future, the delivery of other drugs or 
covalently bound agents should be observed.  
In conclusion, (sC18)2 could be presented in various studies as a lytic peptide with cancer 
selective properties, that was able to overcome the membrane likely by pore formation and 
also accumulated in the cell nuclei. Moreover, it could also be used as cargo delivery system. 
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5.3 Summary and conclusion of N50 and NrTP studies 
In the third part of the thesis, two fusion peptides were investigated regarding their 
internalization and transport capability. The nuclear targeting sequence N50 and the nucleolar 
targeting sequence NrTP were conjugated to the CPP sC18* to gain higher uptake rates and 
a specific targeting to the cell nucleus. All peptide sequences were successfully synthesized 
via SPPS and high purities could be obtained. The CD spectra showed that N50 and NrTP 
alone were not exhibiting a defined secondary structure, but when coupled to sC18*, the 
peptides formed an α-helical structure in the presence of TFE. As it was already shown that 
sC18* alone was also able to form a helix, thus the coupling of the NLS-sequences to this 
amphipathic peptide was the determining factor of the structure formation.  
Due to this, the peptides were also different in their cellular uptake amounts. In both tested cell 
lines (HeLa and MCF-7), the internalization rates of the fusion peptides were extremely 
increased in contrast to the ones of sC18*, N50 and NrTP alone, which was demonstrated by 
flow cytometric and microscopic analysis. It could also be demonstrated that the uptake of the 
fusion peptides in HeLa cells seemed to be higher than in MCF-7 cells, whereby the 
translocation of the peptides were equal in both cell lines. In MCF-7, the internalization of 
NrTP-sC18* was about four times higher than of N50-sC18*. In more detailed microscopic 
studies, it could be observed that both NLS-CPPs localized in the cytoplasm as well as in high 
extent in the nuclei and especially NrTP-sC18* accumulated in the nucleoli. This result was 
also confirmed for HeLa cells but only at low concentrations, whereas in MCF-7 cells, just 
NrTP-sC18* was present in the nucleoli after 30 min of incubation. Interestingly, the amount of 
peptides in the breast cancer cells decreased with longer incubation times, indicating a fast 
degradation of the peptides in the cytoplasm. The incubation of the cells with the CPPs at low 
temperatures did not harm their translocation and localization pattern. This indicated an 
energy-independent direct penetration for their uptake mechanism, which was followed by a 
translocation over the cell nuclei membrane and later on peptide degradation.  
In addition, the peptides cytotoxic profiles differed from each other comparing the cell lines. In 
MCF-7, no toxicity for all peptides could be detected up to a concentration of 100 µM. On the 
contrary, in HeLa cells sC18*, NrTP and N50-sC18* were slightly toxic at 100 µM, whereas the 
fusion of NrTP and sC18* resulted in a toxic peptide version. At 100 µM, no viable cell could 
be examined any more. This was probably correlated to the higher uptake rates in HeLa cells, 
in general. Higher amounts of peptides in the cells could evoke higher cytotoxicity.  
N50-sC18* and NrTP-sC18* were also capable to form complexes with the two DNA vectors 
pEGFP-N1 and pGL4.13, respectively. This was verified by an electromobility shift assay and 
thus a complexation rate could be determined for transfection experiments. Anyway, both 
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transfection studies did not lead to an efficient expression of the reporter genes that were 
encoded on the plasmid DNA. The only slightly promising result was obtained for NrTP-sC18* 
in MCF-7 cells, even when the transfection rate was far below the one with Lipofectamine. In 
general, the transfection rate with Lipofectamine was about 10-times higher in HeLa cells than 
in MCF-7 cells. It is known, that the transfection of cells is a very challenging tool that is 
depending on many various factors such as temperature, concentration, membrane 
composition etc. Other cell lines as well as different protocols should be taken into 
consideration regarding a successful transfection. Within this, also higher peptide/vector rates 
should be investigated, leading to better results. 
Nevertheless, another important property of these fusion peptides could be observed. 
N50-sC18* and NrTP-sC18* were able to efficiently transport the anticancer drug doxorubicin 
in MCF-7 cells, which resulted in a decrease of cell viability. This effect could not be seen in 
HeLa cells and also the microscopic observation led to the hypothesis that the transport of the 
drug was not that high as in the MCF-7 cells. It occurred that the uptake of the CPPs alone 
was higher in HeLa cells, but when complexed with DNA or co-incubated with doxorubicin, the 
treatment of MCF-7 cells was more efficient. This was presumably correlated with the 
interaction of the peptides with the two different cancer plasma membranes.  
In conclusion, one can say that the fusion of a nuclear or nucleolar targeting sequence with a 
cell-penetrating peptide could highly increase the cellular uptake and a selective targeting of 
the nucleus of cancer cells. The two presented new fusion CPPs N50-sC18* and NrTP-sC18* 
already showed interesting features and this work formed the basis for further more detailed 
studies of these promising potential nuclei-targeting peptides. 
To get a better understanding in the translocation of the CPPs N50-sC18* and NrTP-sC18* 
over the cell nuclei membranes of the cancer cells, experiments with fractionated cells and 
isolated nuclei should be performed. Next to this, it should also be investigated, if these fusion 
peptides do also exhibit a certain cell selectivity. Uptake and cytotoxicity studies should also 
be performed with these new CPP variants on non-cancer cells. 
The ability of N50-sC18* and NrTP-sC18* as transport vehicles was only studied with 
doxorubicin. This could be further investigated using other therapeutic agents, covalently 
bound drugs or chemicals that are known to improve the uptake. Moreover, transfection 
studies were just done in a few attempts. Hereby, one could improve the protocol, decrease 
the peptide/plasmid rate or test other cell lines that are known to be better transfectable.   
Furthermore, the exact uptake mechanism of all presented CPPs is still not fully understood. 
By inhibiting specific uptake pathways, the uptake behavior could be further investigated.  
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7 ATTACHEMENT  
 
7.1 List of abbreviations  
 
aa   amino acid  
ACN   acetonitrile  
Boc   tert-butyloxycarbonyl 
CD   circular dichroism 
CF   5(6)-carboxyfluorescein 
Chol   cholesterol 
CH2Cl2   dichloromethane 
CLMS   confocal laser scanning microscopy 
CPP   cell-penetrating peptide 
DCM   dichloromethane 
Dde   1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl 
DIC   N,N-diisopropylcarbodiimide 
DiI   1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate 
DIPEA   N,N-diisopropylethylamine 
DMEM   Dulbecco's Modified Eagle Medium 
DMF   N,N-dimethylformamide 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
DOPC   1,2-dioleoyl-sn-glycero-3-phosphocholine 
DOPE   1,2-dioleoyl-sn-glycero-3-phophoethanolamine 
DOPG   1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] 
DOTA   1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOX   doxorubicin hydrochloride 
EGFP   enhanced green fluorescent protein 
EGFR    epidermal growth factor receptor 
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EMSA   electrophoretic mobility shift assay 
eq.   equivalent 
ER   endoplasmic reticulum 
ESI   electrospray ionization  
Et2O   diethyl ether 
EtOH   ethanol 
FBS   fetal bovine serum 
Fmoc   9-fluorenylmethyloxycarbonyl  
GPMV   giant plasma membrane vesicles 
GUV    giant unilamellar vesicle 
HaCaT  human aneuploid immortal keratinocyte cell line 
HATU O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HCl   hydrogen chloride 
hCT   human calcitonin 
HCT-15  human colon adenocarcinoma cell line  
HEK-293  human embryonic kidney 293 cell line  
HeLa   human cervix carcinoma cell line 
HIV   human immunodeficiency virus 
Hoechst  bisbenzimide H33342 
HPLC   high performance liquid chromatography 
KCN   potassium cyanide 
LB   Luria/Miller 
LDH   lactate dehydrogenase  
LUV   large unilamellar vesicle 
m/z   mass-to-charge ratio 
MßCD   methyl-ß-cyclodextrin 
MCF-7   human breast adenocarcinoma cell line 
MEM   Minimum Essential Medium Eagle  
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MeOH   methanol  
MS   mass spectrometry 
MW   molecular weight 
m/z   mass to charge ratio 
NFκB   Nuclear factor-κB 
NMP   N-methyl-2-pyrrolidone 
NODAGA 4-(4,7-bis(2-tert-butoxy-2-oxoethyl)-1,4,7-triazonan-1-yl)-5-tert-butoxy-
5-oxopentaoic acid 
NLS   nuclear localization signal 
NrTP   nucleolar targeting peptides 
ns   not significant  
o/N   over night 
PB   pyrenebutyrate 
PBS   phosphate buffered saline 
PC-3   human prostate cancer cell line 
PCR   polymerase chain reaction 
PEI   polyethyleneimine 
pGL4.13  Luciferase Reporter Vector 
PMAPs   pH-dependent Membrane Active Peptides 
RCY   radiochemical yield  
Resazurin  7-hydroxy-3H-phenoxazin-3-one-10-oxide 
RNA   ribonucleic acid 
RPMI-1640  Roswell Park Memorial Institute, Cell culture medium 
RT   room temperature 
SM   sphingomyelin (porcine brain) 
SPPS   solid-phase peptide synthesis 
TAE   tris-acetate-EDTA 
t-Bu   tert. butyl 
tBuOH   tert. butyl alcohol 
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TFA   trifluoroacetic acid 
TFE   trifluoroethanol  
TIS/TIPS  triisopropylsilane 
v/v   volume per volume 
w/o   without 
 
Amino acids: 
A  Ala  alanine 
C  Cys  cysteine 
D  Asp  aspartic acid 
E  Glu  glutamic acid 
F  Phe  phenylalanine 
G  Gly  glycine 
H  His  histidine 
I  Ile  isoleucine 
K  Lys  lysine 
L  Leu  leucine 
M  Met  methionine 
N  Asn  asparagine 
P  Pro  proline 
Q  Gln  glutamine 
R  Arg  arginine 
S  Ser  serine 
T  Thr  threonine 
V  Val  valine 
W  Trp  tryptophane 
Y  Tyr  tyrosine   
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